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Etude structurale du mode d’inhibition de l’intégrase du VIH-1 par des 
dérivés de type quinolone: support à la conception rationnelle  
de nouveaux inhibiteurs 
 
par Pierre Van Durm  
 
Résumé 
 
Dans le cadre de la conception de nouveaux agents antiviraux contre le SIDA, l’intégrase 
du VIH-1 constitue une cible de choix car cette enzyme joue un rôle essentiel dans le cycle de 
réplication du virus en intégrant l’ADN viral dans le génome de la cellule hôte. Parmi les 
nombreux inhibiteurs de l’intégrase décrits jusqu’à présent, les dérivés β-dicéto-acide 
représentent une famille importante. Ces composés ont la particularité de posséder un 
groupement capable de chélater le cofacteur métallique Mg
2+
 présent au sein du site actif de 
l’enzyme et essentiel à son activité catalytique. Dans ce travail de thèse, nous avons entrepris 
l’étude du mécanisme d’inhibition de l’intégrase du VIH-1 par des dérivés de type quinolone 
sur base d’une approche expérimentale et théorique. 
 
Une série de quinolones présentant en position 3 un groupement β-dicéto-acide/ester 
capable de chélater le cofacteur métallique Mg
2+
 et en position 6 divers groupements 
(groupements halogène, hydrophile ou hydrophobe) a été synthétisée comme inhibiteurs 
potentiels de l’intégrase du VIH-1. L’activité anti-intégrase de ces composés a été mesurée 
par des tests in vitro en utilisant de l’intégrase surexprimée dans E. coli et purifiée par 
chromatographie d’affinité. L’activité antivirale de ces composés a également été évaluée 
dans des tests ex vivo. 
 
Dans le but d’obtenir la structure tridimensionnelle d’un complexe enzyme-ligand, le 
domaine catalytique de l’intégrase du VIH-1 a été surexprimé dans E. coli et purifiée par 
chromatographie d’affinité. Afin d’améliorer la purété de la protéine active obtenue, d’autres 
techniques de purification ont été testées. 
 
Les études expérimentales (DRX, UV-visible, FT-IR, ATR) et les calculs théoriques 
réalisés sur les composés dicéto-acide sélectionnés ont permis d’identifier les conformations 
les plus stables de la chaîne dicétoacide ainsi que son mode de complexation en solution avec 
le cofacteur Mg
2+
. Afin de déterminer le mode de liaison des composés quinolone au sein du 
site actif de l’enzyme lié à son substrat ADN, un modèle intégrase/ADN a été construit. Les 
études de docking ont mis en évidence un mode de liaison en accord avec les relations 
structure-activité observées. Ces études de modélisation moléculaire nous ont permis de 
proposer un mécanisme d’inhibition de l’intégrase du VIH-1 par des composés quinolone. 
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Structural study of HIV-1 integrase inhibition 
by quinolones: contribution to the 
rational design of new inhibitors 
 
by Pierre Van Durm 
 
Abstract 
 
 In the design of new antiviral agents against AIDS, HIV-1 integrase is an attractive target 
because this enzyme plays an essential role in the virus replication cycle by integrating the 
viral DNA into the host cell genome. Among all integrase inhibitors described to date, the β-
diketo acid derivatives represent an important family. These compounds have the particularity 
to posess a chemical group able to chelate the Mg
2+ 
metal cofactor present in the enzyme 
active site and essential to its catalytic activity. In this thesis, we have undertaken the study of 
the mechanism of inhibition of HIV-1 integrase by substituted quinolone based on 
experimental and theoretical approach. 
 
 A series of quinolone substituted at position 3 by a β-diketo-acide/ester motif able to 
chelate the Mg
2+ 
metal cofactor and at position 6 by various groups (halogen, hydrophilic or 
hydrophobic groups) has been synthesized as potential HIV-1 integrase inhibitors. These 
compounds were evaluated for their anti-integrase activity in in vitro assays using integrase 
overexpressed in E. coli and purified by affinity chromatography. The antiviral activity of 
compounds was also tested in ex vivo assays. 
 
 To obtain the three-dimensional structure of an enzyme-ligand complex, the catalytic core 
domain of HIV-1 integrase was overexpressed in E. coli and purified by affinity chromatography. 
To improve the level of purity of the active protein obtained, other purification techniques were 
tested. 
 
 Experimental studies (XRD, UV-visible, FT-IR, ATR) and theoretical calculations on the 
diketo acid compounds allowed to identify the most stable conformations of the diketoacid 
moiety and its complexation mode in solution with the Mg
2+ 
cofactor. To determine the 
binding mode of developed quinolone within the DNA-bound enzyme, integrase/DNA model 
was built. Docking studies highlighted a binding mode in agreement with the observed 
structure-activity relationships. These molecular modeling studies allowed us to propose a 
mechanism of inhibition of HIV-1 integrase by quinolone compounds. 
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I   Introduction│3 
1   HIV/AIDS: epidemic overview and biological properties 
 
 Human Immunodeficiency Virus Type 1 (HIV-1) is the causal agent of acquired 
immunodeficiency syndrome (AIDS), a widespread disease firstly identified 30 years ago. In 
this first introductive chapter, an overview of the global HIV/AIDS epidemic as well as a 
description of the biological aspects of HIV infection are presented. After a brief historic of the 
discovery of AIDS and the worlwide epidemic situation in section 1.1, a full description of the 
virus and its mechanism of action are given in section 1.2. 
 
1.1. More than 30 years of AIDS 
 
 In 2011, the AIDS epidemic is going down in its fourth decade. Indeed, it’s in the early 
1981’s that the first cases of some extremely rare diseases such as Kaposi’s sarcoma or 
Pneumocystis carinii pneumonia were reported among homosexual men.
1,2
 This new set of 
symptoms, a syndrome in medical terms, which were consistent with damage to the immune 
system, was called Acquired Immunodeficiency Syndrome or AIDS. In 1983, both the Gallo 
and Montagnier groups identified at the same time in the blood of patients the etiological agent 
of AIDS: the Human Immunodeficiency Virus or HIV-1.
3,4
 No sooner had HIV-1 been 
discovered than another human immunodeficiency virus emerged, appearing to be less 
pathogenic, taking longer to damage the immune system after infection and affecting mainly 
population in West Africa.
5,6
 Identified in 1985, this virus was designated HIV-2. Despite its 
origin remains steeped in controversy, most of scientists accept that HIV evolved at some point 
from the closely related Simian Immunodeficiency Virus (SIV), which was transferred from 
wild-living chimpanzees (Pan troglodytes troglodytes) and gorillas (Gorilla gorilla gorilla) to 
humans in West central Africa.
7
 
 
Confronted with a growing worldwide epidemic, a lot of research programs were 
investigated, leading to the approval in 1987 of the first antiretroviral agents, the Azidothymidine 
(AZT), able to block the HIV reverse transcriptase (RT) which constitutes one of the key 
enzymes for the viral replication.
8
 This discovery opened the way for the design of new anti-HIV 
therapies, with the beginning in 1995 of bitherapies associating two RT inhibitors in order to 
have an higher efficiency against the virus.
9,10
 In 1996, the commercialization of the anti-HIV 
protease (PR) drugs led to the clinical use of a tritherapy (Highly Active Antiretroviral Therapy, 
or HAART) based on the synergic effect of two anti-HIV RT and one anti-HIV PR inhibitors.
11
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This treatment marked by undetectable viral load in treated HIV-seropositive patients was 
quickly considered as a solution to cure AIDS. Currently, this great enthusiasm is falling due to 
the appearance of resistant viral strains and strong side effects associate with this treatment. 
Even though HAART extend and improve the lives of people living with HIV, it does not allow 
to eradicate HIV in the human body.   
 
Nearly thirty years after its first appearance, the AIDS epidemic is still nowadays the 
leading case of mortality and morbidity in the world.
12
 In 2009, there were 33.3 million people 
living with HIV and 1.8 million of AIDS-related deaths. Nevertheless, since few years, the 
spread of AIDS epidemic seems to be halted and begun to reverse. In 2009, there were an 
estimated 2.6 million people who became newly infected. This is 19 % fewer than the 3.1 
million people newly infected in 1997, the year in which annual new infections peaked (Figure 
1.1a). The number of annual worldwide AIDS-related deaths is steadily decreasing from the 
peak of 2.1 million in 2004 to an estimated 1.8 million in 2009 (Figure 1.1b).  
   
                             a) Number of people newly infected with HIV 
 
 
        b) AIDS-related deaths 
 
            
Figure 1.1. Global HIV trends from 1990 to 2009.
12
 
 
Sub-Saharan Africa remains the epicenter of epidemic with 22.5 million people living with 
HIV, 68 % of the global total. Moreover, the estimated 1.3 million people who died of HIV 
comprised 72% of the global total of 1.8 million deaths attributable to the epidemic. 
 
Despite the declining of the HIV spread, the number of new infections and AIDS-related 
deaths are still high. Consequently, the research of new and improved antiretroviral treatments 
remains today essential.  
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1.2. Biological aspects of HIV-1 infection  
  
 HIV-1 belongs to the retrovirus family, a group of viruses that contains positive single-
stranded RNA as genetic material which is retro-transcribed into proviral DNA by a reverse 
transcriptase. Because a long latency period occurs between the infection (during sexual 
relations, blood-borne or maternal-fetal transmission) and the first symptoms of the disease, 
HIV-1 is classified as a lentivirus.  
 
 1.2.1. HIV pathogenesis
13
 
  
Once in the human body, HIV targets cells that express CD4 receptors at the surface of the 
plasmic membrane such as T lymphocytes, dendritic cells or macrophages. HIV infection can 
be divided into three basic stages based on the CD4
+
 T cell counts and the level of virus in the 
blood stream of patients: the acute infection, the latency stage and AIDS (Figure 1.2). In the 
first stage of infection, or acute infection, a fast viral replication occurs leading to an abundance 
of viruses in the peripheral blood and a marked drop in the numbers of circulating CD4
+
 T cells 
(HIV budding from the plasma membrane causing cells damage, attacks of cytotoxic T 
lymphocytes, appearance of syncytia, apoptosis). During this period (usually 2-4 weeks post-
exposure) most individuals develop some symptoms such as influenza or mononucleosis-like 
illness. These ones disappear within two weeks, when a strong immune defense reduces the 
number of viral particles in the blood stream, marking the start of a latent period (which can 
last until 20 years) during which no clinical symptoms are observed. Nevertheless, the 
concentration of CD4
+
 T cells progressively decreases over time. When the cells count is below 
200 cells/mm
3
, AIDS is associated to opportunistic infections such as Kaposi’s sarcoma, 
Pneumocystis carinii pneumonia or toxoplasma.   
 
 
 
Figure 1.2. Evolution of the viral load (red curve) and CD4 cells counts (blue curve) over the average course of  
untreated HIV infection.
13
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 1.2.2. Structure and genome of HIV-1
14
 
 
 Mature HIV-1 virions (Figure 1.3) are roughly spherical particles varying in diameter from 
1000 to 3000 Å. The outer envelope consists of a lipid bilayer studded with two glycoproteins: 
the envelope glycoprotein (gp120 or SU) and a transmembranar glycoprotein (gp41 or TM). 
The matrix protein (p17 or MA) forms a layer under the viral membrane and is essential for the 
viral stability. The genetic material of the virus is enclosed by a coating of capsid proteins (p24 
or CA). This core contains two copies of single-stranded RNA tightly bound to nucleocapsid 
proteins (p7 or NC), viral proteins (p6, Tat, Rev, Vif, Nef, Vpr and Vpu) as well as three key 
enzymes for viral replication: HIV-1 RT, HIV-1 PR and HIV-1 integrase (IN). 
 
 
 
Figure 1.3. Structure and organization of the HIV-1 genome and virion.
14
 
  
The HIV-1 genome encodes nine open reading frames flanked by two Long Terminal Repeat 
sequence (U5 and U3 LTR) which regulate viral gene expression via their interaction with 
multiple viral and host factors. Among these nine genes, the gag, pol and env genes are 
common to all retroviruses: 
 
 The gag (group-specific antigen) gene provides the basic physical infrastructure of the 
virus by encoding the matrix, capsid, nucleocapsid and p6 proteins. 
 The pol (polymerase) gene encodes three enzymes essential for the virus replication: 
RT, PR and IN.  
 The env (envelope) gene encodes for viral envelope glycoproteins gp120 and gp41. 
 
The six additional genes of HIV-1 genome (tat, rev, vif, nef, vpr and vpu) encode for accessory 
and regulatory proteins. 
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 1.2.3. HIV-1 life cycle 
 
 Like all other retroviruses, HIV-1 uses the CD4+ T cell’s machinery to replicate itself. The 
replication cycle can be divided into 5 major steps (Figure 1.4): the virus entry into host cell, 
the uncoating of the capsid core and reverse transcription of viral RNA, the nuclear entry and 
the integration of viral DNA into the host cell DNA, the transcription and translation of viral 
polyproteins, the budding and maturation of the new retroviral particle.  
 
 
 
Figure 1.4. HIV-1 replication cycle.
15
 
 
I. Entry 
 
 The early phase of the replication cycle begins with the attachment of the envelope 
glycoprotein gp120 present at the surface of viral particles to the CD4 T-cell receptor. This 
interaction triggers a conformational change in gp120 leading to its binding to a chemokine 
coreceptor such as CXCR4 and CCR5.
16
 This second interaction induces new conformational 
shifts in the envelope glycoprotein gp120 and lead to the dissociation of gp120 from gp41. 
Finally, the insertion of gp41 fusion peptide into the membrane results in the fusion of viral and 
cell membrane and the release of the viral core into the cytoplasm.
17
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II. Uncoating and reverse transcription
18
 
 
 Although early work suggested that the viral core undergoes a disassembly immediately 
after its release into the cytoplasm
19
, recent studies proposed that capsids remain intact until 
HIV-1 incoming complexes reach the nuclear membrane and that uncoating occurs at the 
nuclear pore upon completion of reverse transcription. The retrotranscription of the viral RNA 
in viral DNA is initiated by a cellular tRNA(Lys) and catalyzed by HIV-1 RT within reverse-
transcription complexes (RTCs) surrounded by the intact capsid core. HIV-1 RT requires the 
RNA-dependent DNA polymerase activity to synthesize DNA from an RNA template and the 
Rnase H activity to degrade the RNA after the first strand DNA has been synthesized. Vif 
would protect, in cells producing viruses, the newly formed double-strand DNA by preventing 
the deamination reaction of deoxycytidine to deoxyuridine in viral DNA catalyzed by the host 
APOBEC3G protein.
20,21
 During reverse transcription, HIV-1 RTCs move rapidly toward the 
nuclear compartment, using microtubules and actin filaments to reach the nuclear pore.
22
 There, 
the completion of reverse transcription and the formation of the central DNA Flap facilitate 
uncoating.
23
 Recent work indicates that the host protein TRIM5α promotes the rapid and 
premature disassembly of viral capsids thus abrogating productive reverse transcription.
24,25
 
Nevertheless, TRIM5α-mediated restriction is modulated by the host protein Cyclophilin A 
(Cyp A) which could also interact with the capsid of HIV-1.
26
  
 
III. Nuclear entry and integration  
 
 In order to form the provirus, the viral genome must cross the cell’s nuclear membrane to 
integrate the host cell DNA. Upon uncoating of the viral core, the viral complex becomes a pre-
integration complex (PIC) competent for import into the nucleus. Although the complete 
identification of PIC components remains uncertain, viral proteins such as IN, MA, Vpr, RT 
and the cellular protein HMGI(Y) have been identified as PIC components.
27
 The HIV-1 active 
nuclear import model proposed is a process by which the nuclear localization signal (NLS) 
identified into IN and MA proteins is recognized and bound by a member of the importin 
family of nuclear import receptors (importin-α and -β).28 Among its many roles play in HIV-1 
infection, Vpr mediates the targeting of the PIC to the nucleus via its interaction with importin-
α, ultimately promoting binding to nuclear pore proteins.29 The RAN-GDP/RAN-GTP gradient 
that exists between the cytoplasm and nucleus serves to drive the direction of the import 
complex whereas the movement into the nucleus occurs through nuclear pore complexes 
(NPCs) containing nucleoporins (NUPs) that assemble to form the larger pore complexes.  
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It has been shown that NUP153 plays a central role in PIC nuclear import by interacting via its 
C-terminal domain with HIV-1 IN. The dynamic distribution of the C-terminal domain of 
NUP153 throughout the channel as well as its exposure to the cytoplasm under active 
transcription offers the PIC a direct link from the cytoplasm to the chromosomal DNA 
environment best suited to support integration catalyzed by HIV-1 IN (This will be detailed in 
chapter 3).
28,30
 Cellular DNA binding proteins have been described to interact with IN and 
seem therefore critical for the integration process. Lens epithelium-derived growth factor 
(LEDGF/p75), a protein implicated in the regulation of gene expression and in the cellular 
stress response, was found to interact with IN and seems to be required to dock the PIC to the 
host chromatin.
31
 
 
IV. Transcription and translation of viral proteins 
  
Once integrated, the HIV proviral genome is transcribed by the host RNA polymerase II. 
Activation of transcriptional elongation occurs following the recruitment of HIV-1 Tat protein 
to the transcription machinery via a specific interaction with an RNA regulatory element called 
TAR (Transactivation Response Element). After binding to TAR RNA, Tat stimulates a kinase 
called TAK (Tat-associated kinase) which hyperphosphorylates RNA polymerase and 
stimulates its activity.
32
 The interaction of HIV-1 Nef protein with Tat may also enhance the 
HIV-1 gene expression.
33
 After transcription, a set of spliced mRNAs are free to move away 
from the nucleus and are translated into viral polyproteins in the cytoplasm using host 
ribosomes. The unspliced mRNA, which constitutes the genetic material of the new virions, is 
efficiently transported by the HIV-1 Rev protein through its binding to the Rev-responsive 
element (RRE) sequence.
34
 
 
V. Budding and maturation
35
 
 
Viral particle formation is a multi-step process driven by the viral polyprotein Gag. Gag 
contains three conserved regions (MA, CA, NC) that perform distinct functions during viral 
assembly: the N-myristoylated MA domain targets the protein to cellular membrane, the CA 
domain makes important protein-protein interactions during particle assembly, and the NC 
domain captures the viral RNA genome and couples RNA binding and assembly. The viral 
protease activated during assembly cleaves Gag to generate a set of new proteins which then 
reassemble to form the distinct layers of the mature virion. Finally, the budding of the new 
retroviral particle is mediated by the recruitment of cellular proteins.  
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Vpu, a membrane-associated accessory protein that is unique to HIV-1, enhances the release of 
progeny virions from infected cells by antagonizing tetherin, an interferon-regulated host 
restriction factor that directly cross-links virions on host cell-surface.
36
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2   HIV antiretroviral therapy 
 
 For over 30 years, AIDS research focused on both the development of vaccines and the 
discovery of antiretroviral drugs able to block the HIV-1 replication cycle. Despite no vaccines 
have been shown effective, a success has been achieved in anti-HIV drug discovery. In the first 
section of this chapter, the different classes of anti-HIV-1 drugs and their mechanism of action 
are presented. Current status and future prospects of antiretroviral therapies are finally 
discussed in section 2 and 3, respectively.    
 
2.1. Twenty-five antiretroviral drugs licensed 
 
 The currently 25 FDA- and EMEA-approved anti-HIV-1 drugs can be divided into four 
groups based on the step blocked in the HIV-1 life cycle: entry inhibitors, RT inhibitors, IN 
inhibitors and PR inhibitors.  
  
2.1.1. Entry inhibitors  
 
One of the key steps in the infection of the host cells by HIV-1 is the interaction of the 
envelope glycoprotein gp120 with CD4 and CXCR4/CCR5 chemokine receptors. These 
associations lead to the insertion of the gp41 fusion peptide into the host cell membrane. Entry 
inhibitors hold considerable potential for the treatment of HIV infection, particularly in patients 
harboring viruses resistant to RT and PR inhibitors. Currently, only antagonists that block 
fusion and CCR5 binding have been approved by the FDA for treatment of HIV-infected 
patients. 
 
 Pharmacological agents that disrupt gp41-mediated membrane fusion, also called fusion 
inhibitors, were the first entry inhibitors to be approved for the treatment of HIV infection. 
Enfuvirtide
37
 (Figure 2.1) is a polypeptide of 36 amino acids that mimics the C-terminal 
region of gp41. Due to its poor oral bioavailability, this drug has to be administered twice daily 
by subcutaneous injection, inevitably leading to injection site reactions including erythema, 
induration, nodules and cysts. Moreover, mutations within gp41 seem to emerge promptly in 
patients upon monotherapy with enfuvirtide.
38
 A number of other next-generation peptidic 
fusion inhibitors active against some enfuvirtide-resistant strains are under investigation.
39,40
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However, since peptidic fusion inhibitors are not orally bioavailable and must be administered 
via injection, another approach based on the development of small molecule inhibitors of gp41-
mediated fusion was developed.
41
 
 
 Maraviroc
42
 (Figure 2.1) is the only CCR5 co-receptor antagonist used in the treatment of 
HIV-1 infection. Orally administered twice daily, it appeared to be well tolerated and is 
indicated for use in combination with other antiretroviral agents in treatment-experienced adult 
patients infected with multidrug-resistant, CCR5 tropic HIV-1.
43
 Another CCR5 antagonist, 
vicriviroc
44
 (Figure 2.1), is currently in phase III clinical trials. In addition, others inhibitors 
seem to be promising candidates for further development.
45,46
 However, there are some 
concerns regarding the use of this class of anti-HIV-1 drugs as treatment because blocking the 
CCR5 co-receptor could drive the virus to use the other CXCR4 co-receptor, leading to the 
emergence of resistant HIV strains and a more aggressive disease.
47
 Therefore, there is also a 
need to develop effective drugs able to block CXCR4 co-receptor. Thus far, none of the 
CXCR4 antagonists in development have shown promise in HIV clinical trials. 
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Figure 2.1. Structure of HIV-1 entry inhibitors. 
  
2.1.2. RT inhibitors 
 
The first anti-HIV-1 drug approved for the treatment of AIDS was AZT, also known as 
zidovudine
8
, a nucleoside RT inhibitor (NRTI). Since there, extensive research has led to the 
design of new nucleoside-based analogs as well as non-nucleoside RT inhibitors (NNRTIs). 
 
 Once phosphorylated by cellular kinases to their triphosphate derivatives, NRTIs interact 
with the DNA polymerase active site of RT and are incorporated into the growing DNA. Due to 
the lack of 3’-hydroxyl group, these compounds prevent the incorporation of the incoming 
nucleotide that results in terminating the elongation of the growing DNA double strand.  
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In addition to the 7 currently approved NRTIs, multiple compounds are in phase II or III 
clinical trials (Figure 2.2).
48
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Figure 2.2. Structures of NRTIs currently approved by the FDA (top 2 lines) and undergoing phase II or III 
clinical trials. 
 
Despite these are extensively used in HAART, their effectiveness can be limited by the 
emergence of drug resistance and adverse events.  
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Due to their poor selectivity, these compounds exhibited acute toxicity. The inhibition of 
mitochondrial DNA polymerase gamma (mtDNA pol γ) is one of the major causes of all 
NRTIs-related adverse effects.
49
 Besides RT mutations, NRTIs resistance might arise through a 
repair reaction called pyrophosphorolysis whereby the nucleoside inhibitor is removed from the 
growing viral DNA chain, allowing reverse transcription to resume.
50
 Metabolic activation of 
NRTIs also represent a relevant problem for this class of compounds with the first 
phosphorylation being generally assumed as the rate-limiting step.
51
 
 
To overcome the problem of NRTIs activation process, nucleotide analog prodrugs 
(NtRTIs) have been developed with the aim to deliver nucleoside analogs monophosphates. 
FDA-approved tenofovir disoproxil fumarate
52
 (TDF) (Figure 2.3) is widely used in 
antiretroviral regimens for both treatment-naive and -experienced patients and is active against 
some nucleoside-resistant strains of HIV-1. Nevertheless, cross resistance with other NRTIs as 
well as side effects such as acute renal failure are associated to the clinical use of this drug. 
Recently, GS-9131
53
 (Figure 2.3) characterized by improved resistance profile, safety and long 
term tolerability has been identified. This compound is considered as a promising drug 
candidate for the treatment of HIV-1-infected individuals. 
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Figure 2.3. Structures of NtRTIs. 
   
NNRTIs inhibit RT activity by binding noncompetitively to an allosteric site located about 15 Å 
from the catalytic site. This interaction induces a conformational change within the enzyme that 
blocks the RT polymerase activity. Contrary to NRTIs, these drugs are relatively specific, that confers 
on them low side effects. A major limitation to the success of the first generation of NNRTIs (Figure 
2.4, first line) is the rapid emergence of HIV-1 variants resistant to these drugs which contain one or 
more mutations in the non-nucleoside inhibitor binding pocket of RT.
54,55
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In this context, a second generation of NNRTIs with a better resistance profile and an increased 
genetic barrier to the development of resistance was developed. Among these next generation 
NNRTIs, etravirine
56
 was approved by the FDA whereas four more are currently under clinical 
development (Figure 2.4, second and third line).
55
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Figure 2.4. Structures of first generation FDA-approved (first line) and second generation NNRTIs. 
 
2.1.3. IN inhibitors  
 
The integration of the viral DNA into the host cell genome is an essential step in the viral 
replication cycle. This process is catalyzed by HIV-1 IN which is considered as one of the most 
promising antiviral drug targets. HIV-1 IN inhibitors currently approved or in clinical 
development were identified as strand transfer inhibitors (INSTIs). They block the DNA 
strand transfer reaction of the enzyme by interacting with the magnesium cofactor (Mg
2+
) at the 
enzyme catalytic site. Their mechanism of action will be described in more details in chapter 3. 
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At the moment, raltegravir
57
 (Figure 2.5) is the only FDA- and EMEA-approved HIV-1 
IN. This one is an orally, well tolerated active compound dosed 400 mg twice daily and 
metabolized by glucuronidation.
58
 Raltegravir is only licensed in combination with other 
antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult 
patients who have evidence of viral replication and HIV-1 strains resistant to multiple 
antiretroviral agents.
59,60
 On the basis of its metabolic profile and preclinical data, raltegravir 
has a low propensity to be involved in clinically meaningful drug interactions.
61
 Similar to all 
antiretroviral drugs, raltegravir is associated with treatment failure, i.e., partial or complete loss 
of viral suppression. HIV resistance to raltegravir is the consequence of mutations located close 
to the IN active site, which can be divided into three main evolutionary pathways: the N155H, 
the Q148R/H/K and the Y143R/C pathways.
62
 Each of these primary mutations can be 
accompanied by a variety of secondary mutations that both increase resistance and compensate 
for the variable loss of viral replicative capacity that is often associated with primary resistance 
mutations.
63
 Elvitegravir
64,65
 (Figure 2.5) is the next most advanced INSTI currently in phase 
III clinical development. Like raltegravir, it has also shown potent antiviral activity in vivo 
against HIV-1 carrying resistance mutations to multiple antiretroviral drug classes when it is 
administered with active background therapy.
66
 Nevertheless, resistance mutations 
(Q148R/H/K, N155H, E92Q and T66I as major mutations) and cross-resistance to raltegravir 
have been identified in phase II clinical studies.
67
 Recently, a second generation once daily 
unboosted INSTI, S/GSK-1349572
68
 (GSK-572), that retains antiviral activity in clinical 
isolates resistant to raltegravir and elvitegravir has been developed (Figure 2.5). This 
compound was recently started phase III clinical trial.  
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Figure 2.5. Structures of raltegravir, elvitegravir and S/GSK1349572. 
  
2.1.4. PR inhibitors  
 
HIV-1 PR is responsible for the cleavage of polyproteins to the structural proteins, thereby 
providing the new mature virion.  
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PR inhibitors interfere with this late stage of the viral replication cycle and prevent the 
formation of infectious virus. Currently, there are 10 FDA-approved PR inhibitors which can 
be divided into two major classes: the peptidomimetic and non-peptidic inhibitors (Figure 
2.6).
69
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Figure 2.6. Structures of the 10 FDA-approved peptidomimetic and non-peptidic PR inhibitors. 
 
Peptidomimetic inhibitors contain a hydroxyethylene core mimicking the transition-state 
formed during the HIV-1 PR-catalyzed proteolysis of viral polyproteins.  
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Most of PR inhibitors are prescribed with a lowdose of ritonavir as boosting agent because it 
was recognized that this drug reduces the metabolism of administered compounds through 
hepatic and intestinal cytochrome P450 3A4 inhibition, leading to the dramatical improvement 
of bioavailability and half-life.
70
 Like other drug molecules with peptidic character, the 
efficiency of these agents is limited by their poor bioavailability. Furthermore, this class of 
drugs suffers from the ever-present problem of resistance and cross-resistance as well as a 
specific toxicity profile (e.g., gastrointestinal disturbances and lipodistrophies). 
 
This has prompted the search for non peptidic inhibitors, with tipranavir
71
 which 
contains a dihydropyrone ring as a central scaffold instead of the peptidomimetic 
hydroxyethylene. It was approved by the FDA in 2005 for the treatment of highly experienced 
patients with resistance to multiple PR inhibitors. Tipranavir is a potent inducer of its own 
metabolism through induction of the cytochrome P450 expression, which results in a need for 
dose ritonavir boosting.
70
 Despite its virological benefits, this antiretroviral agent presents 
diverse side effects such as diarrhea, nausea and vomiting.  
 
2.2. Current status of antiretroviral therapy
72
 
 
Since the introduction of combination therapy in 1990s, termed Highly Active 
Antiretroviral Therapy (HAART), the number of people dying from AIDS has 
significantly decreased.
11
 Current HAART regimens combine two or three drugs that target 
more than one step of the virus life cycle: NRTIs, NNRTIs and PR inhibitors. The clinical 
benefits of using multi-therapies are the synergic effects of the different drugs, side effects 
decrease as well as the improvement of drug resistance profile. The decision to begin 
antiretroviral therapy for any patient must balance the burden and toxicity of the drug regimen 
against the benefits of decreased HIV-related morbidities and increased life expectancy. For all 
patients, the goal of the therapy is the reduction of plasma viral load to below detectable levels 
(50 copies/ml). Several factors need to be considered when choosing an initial regimen such as 
comorbidities (e.g., cardiovascular, renal, or psychiatric disease), potential adverse drug effects, 
interactions with other medications the patient may be receiving and patient adherence. Based 
on the results of genotypic-resistance testing, a regimen should be constructed to maximize the 
probability of virologic suppression while minimizing adverse effects, toxicities, and pill 
burden.
 
 Most preferred regimens for initiating therapy include a dual-NRTI backbone in 
combination with an NNRTI, a ritonavir-boosted PR inhibitor or an INSTI.  
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A combination of TDF and emtricitabine has become the most commonly used dual-NRTI 
backbone in first-line therapy because of superior virologic efficacy, reduced drug resistance 
and less toxicity than other NRTI regimens.
73-75
 The choice of whether to use an NNRTI, a 
boosted PI, or an INSTI needs to be individualized. The combination of TDF, emtricitabine 
and efavirenz, co-formulated into a once daily Atripla
76
 tablet has markedly simplified the drug 
regimen for HIV-1 infected patients. Clinical assessment, together with measurement of HIV 
RNA levels and CD4 cell counts, should be used to assess the need to change therapy. Single 
drug substitutions of individual antiretroviral, usually within the same class, is recommended 
for toxicity, drug-drug interaction or intolerance. If the patient experiences resistance, the 
switch of the entire regimen from first to second line is required. At least two, and preferably 
three, fully active drugs should be included in the new regimen, ideally using agents from at 
least one new class. 
 
There is no doubt that HAART has substantially reduced the death rate from AIDS and 
improved the quality of life for HIV-1-infected patients. Nevertheless, the issues of the 
currently used drugs such as resistance and the formation of HIV-1 latent reservoirs in patients 
undergoing HAART show need to design new antiretroviral agents.  
 
2.3. New and emerging targets for HIV therapy  
 
As discussed above, a number of significant problems associated to the clinical use of the 
currently anti-HIV drug are observed. Although the discovery of anti-HIV drugs that belong to 
the already existing classes are still needed to deliver new drugs that benefit AIDS patient, the 
design of new agents with novel mechanism of action could be of greater benefit, as they could 
overcome the current resistance mechanism or prevent HIV-1 infection. New agents in 
preclinical and clinical development are presented below. 
 
 2.3.1. Pharmacological cycline dependent kinase inhibitors 
 
 Cyclin dependent kinases (CDKs) are cellular enzymes which bind to a protein called 
cyclin to form cyclin/CDK complexes involved in HIV-1 Tat transactivation. Upon cellular 
stress, natural CDK inhibitor p21/waf1 is normally induced and regulates cell cycle progress.   
Recent studies have shown that HIV-1 latently infected T cells do not induce expression of 
p21/waf1 after injury to the host cell.
77
 Consequently, CDKs could be targeted for both 
inhibition of HIV-1 replication and HIV-1 latent reservoirs using drugs that mimic the natural 
CDK inhibitors.  
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R-roscovitine (Figure 2.7), currently in phase I cancer clinical trials, reversibly competes for 
ATP binding site in CDKs.
78
 It has been shown in preclinical studies to inhibit HIV-1 
production and induce apoptosis in latent and activated HIV-1-infected cells without the release 
of infectious virions.
79
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Figure 2.7. Structure of R-roscovitine. 
   
2.3.2. Modified anti-sense oligonucleotides 
 
Modified anti-sense oligonucleotides are short single strands RNAs designed to have a 
high affinity for their target sequence and inhibit gene expression. The inhibitory effect is 
largely based on strong binding of antisense oligonucleotides to the target mRNA, which can 
block splicing events or the elongating ribosome through steric hindrance.
80
 Moreover, 
cleavage of the viral RNA could also mediated by recruitment of RNase H.
81
 One antisense 
drug, HGTV43
82
 is starting Phase II trials.  
 
2.3.3. Immune-based therapies 
 
As described in chapter 1 (section 1.2.3), virus entry is mediated by the binding of the 
envelope glycoprotein gp120 to the Human T cell receptor CD4. The monoclonal antibody 
(MAb) ibalizumab
83
 (TNX-355) is a humanized IgG4 MAb which interferes with viral entry 
by interacting with the antibody binding site of the CD4 receptor distinct from the site required 
for the binding of gp120 and major histocompatibility complex proteins which play an 
important role in the immune system. Ibalizumab does not inhibit gp120 binding to CD4 but 
appears to exert its antiviral effect by post-binding conformational effects that prevent CD4-
bound gp120 from interacting with CCR5 or CXCR4. Administered by intravenous infusion 
once every other week, TNX-355 was found in phase II clinical trial to produce dose dependent 
reduction in HIV-1 viral load and increase in CD4 cell count.
84
 Moreover, synergistic effect 
with the fusion inhibitor enfurvirtide was observed.
85
 
 
    I   Introduction│21 
The development of an effective HIV-1 vaccine remains nowadays one of the major goals 
of AIDS research to end the epidemic. Traditional methods of vaccine design including live 
attenuated virus, whole killed virus or subunit proteins are thought to be too dangerous or 
ineffective in protecting against HIV. Current most advanced HIV-1 vaccine trials are based on 
the use of viral vectors which are rendered replication-defective by mutations and by deletion 
of adenovirus genes. These are replaced by HIV genes to form replication-incompetent viruses 
able to insert their genomes into the host cell DNA and expressed HIV proteins-mediated 
immunity response.
86
  One of the most advanced vaccine regimen combines the Alvac-HIV and 
Aidsvax vaccines. Alvac-HIV uses the canarypox virus vector containing the three env, gag 
and pol HIV-1 genes whereas Aidsvax vaccine contains recombinant surface glycoprotein 
gp120. The co-administration of the two vaccines could both stimulate the HIV specific T 
lymphocytes and activate neutralizing anti-HIV antibodies. An induction of prespecified 
cellular and humoral immune responses as well as no serious adverse events and HIV-1 
infections associated to Alvac-HIV/Aidsvax vaccine regimen has been reported in phase III 
clinical trial. Although this treatment has low-level efficacy in reducing HIV-1 acquisition, it 
offers insight for future research.
87
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3   Focus on HIV-1 IN 
 
HIV-1 IN is an attractive target for new AIDS chemotherapeutics. This enzyme which 
belongs to the family of proteins with DDE motif, also called polynucleotidyl transferase 
family, is essential to the virus replication cycle by integrating viral DNA into the host cell 
genome. Moreover, it has no human counterparts, suggesting that low side effects could be 
associated with the enzyme inhibition. This third part of the introduction focuses on HIV-1 IN. 
In the first section, key role played by the enzyme in the integration process is described. The 
second section reports the HIV-1 IN structure whereas the different classes of HIV-1 IN 
inhibitors and their mechanism of action are presented in the third section.  
 
3.1. Catalytic activities  
 
 Integration of viral DNA into the host-cell chromosome is catalyzed by HIV-1 IN through 
a two general sequential reactions (Figure 3.1) that are also observed for polynucleotidyl 
transferase family enzymes.
88,89
 The first one, named 3’-processing (3’-P), occurs in the 
cytoplasm and more specifically in a preintegration complex (PIC) including viral DNA, viral 
proteins (RT, IN, …) and host cellular proteins (HMG-A1, LEDGF/p75, …).27 This process 
corresponds to an endonucleolytic cleavage at each 3’ ends of double stranded viral DNA 
extremities. IN specifically recognizes two inverted DNA sequence (U3 and U5 LTR) and 
cleaves GT dinucleotides immediately 3’ to a conserved CA dinucleotides to produce two 
reactive 3’OH ends. Following 3’-P reaction, PIC is actively transported across the nuclear 
membrane into the nucleus and targeted to the host genomic DNA to perform the second 
catalytic reaction catalyzed by IN, called strand transfer (ST). The two 3’-OH ends generated 
during 3’-P attacks two phosphodiester bonds (spaced 5 base pairs apart) of cellular DNA to 
inserts the viral DNA into the host cell genome. Finally, the integration process ends by the 
cleavage of the two nucleotides at the 5’-end and gap filling from the 3’-end of the host 
genomic DNA probably by cellular DNA repair enzymes.
90
 
 
 IN may catalyze a third reaction, named disintegration, which corresponds to the apparent 
inverse reaction of ST.
91
 Contrary to 3’-P and ST reactions which require full-length protein, 
disintegration can be catalyzed by the catalytic domain alone (IN
50–212
) or by truncated proteins 
(IN
1–212 
or IN
55–288
).
92
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Although it is not clear whether it may occur in vivo, this process is observed in vitro and was 
widely used for testing the competitive mechanism of some inhibitors. 
  
                          
 
 
Figure 3.1: Mechanism of viral DNA integration catalyzed by HIV-1 IN.
93 
 
 All three processes require a metallic cofactor such as Mn
2+
 or Mg
2+
. Some experimental 
evidence suggest that Mg
2+
 is more physiologically relevant: (i) IN displays strong non-specific 
nuclease activity in the presence of Mn
2+
.
94
 (ii) The sequence variation at both viral DNA ends 
is much greater in the presence of Mn
2+
 than in the presence of Mg
2+
.
95
  
 
 Crystallographic studies of proteins belonging to the polynucleotidyl transferase family 
and catalyzing 3’-P and ST have shown that these reactions occured by a one-step SN2-like 
mechanism.
96-98
 Crystal structures of B. halodurans RNase H1/RNa-DNa complexes allowed 
the reconstruction of the course of 3’-P reaction and point to the involvement of a general two-
metal ion catalysis implicating water molecules (Figure 3.2).
99,100
 In this mechanism, metal ions 
are located on two sides of the scissile phosphate and form stable octahedral complex: the B-
site Mg
2+
 coordinates, positions and activates the nucleophile (water molecule) to attack the 
phosphorus atom of the scissile phosphate (Figure 3.2a) whereas the A-site Mg
2+
 stabilizes the 
transition state and the leaving group. This step is associated to the move of the two metal ions 
close together to promote the formation of the transition state. Interestingly, the 5'-phosphate is 
displaced from the active site after the completion of the hydrolysis to form a stable complex in 
which the two Mg
2+
 are octahedrally coordinated by a conserved DDE motif, water molecules 
and 3’-OH extremity of the processed strand.  
3’-processing (3’-P) 
Strand transfer (ST) 
DNA repair 
cytoplasm 
nucleus 
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Recently, Maertens et al. reported an SN2 mechanism for ST reaction based on the 
superimposition of crystal structures of PFV IN/DNA complexes.
101
 In this mechanism, the 3’-
hydroxyl group of viral DNA coordinated to B-site Mg
2+
 is positioned to perform an in-line 
SN2 nucleophilic substitution at the phosphorous atom of the scissile phosphodiester in target 
DNA (Figure 3.2 b). As a result, the viral DNA-target DNA phosphodiester shifts from its pre-
strand transfer position (~ 110° rotation) and is thereby ejected from the active site.  
 
                                                   
 
                                                                 
                      
Figure 3.2. Proposed catalytic mechanism of 3’-P and ST reactions. Mg2+ ions and water molecules are shown as 
green and red spheres, respectively. DDE acidic residues are shown as grey sticks, RNA/DNA and viral DNA 
substrate are shown as yellow sticks whereas target DNA is shown as purple sticks. a) Endonucleolytic cleavage 
catalysed by RNase H1 enzymes. Left: Pre-reactive state obtained with RNA/DNA hybrid substrate (PDB code 
1ZBL).
99
 Right: Product complex obtained with 5'-phosphorylated RNA/DNA hybrid (PDB code 2G8V).
100
 b) ST 
reaction catalyzed by PFV IN. Left: Pre-catalytic target capture complex obtained with 3’-processed viral DNA 
and target DNA in the absence of Mg
2+
 ions (PDB code 3OS2).
101
 Right: Post-catalytic strand transfer complex 
obtained with 3’-processed viral DNA and target DNA in the presence of Mg2+ ions (PDB code 3OS0).101 
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3.2. Structure  
 
HIV-1 IN is a metalloenzyme of 32 kDa (288 amino acids) which belongs to the 
polynucleotidyl transferase family. It is composed of three functional domains each required 
for catalytic reactions (Figure 3.3).  
 
 The N-terminal domain (amino acids 1-49) contains a HHCC zinc-finger motif that 
promotes protein multimerization. 
  
 The catalytic core domain (CCD) (amino acids 50-212) contains a DDE triad 
conserved among the polynucleotidyl transferase family. These residues are involved 
in the complexation of metallic cofactor(s) (Mg
2+
) essential for the catalytic activity.  
 
 The C-terminal domain (amino acids 213-288) binds non-specifically to viral DNA 
and stabilizes the IN/DNA complex.  
 
To date, crystal structure of full-length IN alone or in complex with its cognate DNA 
substrate has not yet been resolved. Nevertheless, the structures of the isolated N-terminal (IN
1-
49
) and C-terminal (IN
219-270
) domains have been determined by NMR (Figure 3.3).
102,103
 IN
1-49
 
has a structure consisting of four α helices stabilized by a Zn2+ cation tetrahedrally coordinated 
by a HHCC motif. IN
219-270
 structure consists of five antiparallel β-strands forming a β-barrel 
and adopting a SH3-like fold. The structure of the catalytic core domain (CCD) has been 
determined by crystallographic studies and is built around a mixed α/β structure, with five β-
sheets and six α-helices.104-106 The active site residues D64, D116 and E152 are presented by 
the middle of β1-sheet, coil and α4-helix, respectively. Crystal structures of the isolated CCDs 
available to date show a single Mg
2+
 ion coordinated by the two aspartate residues D64 and 
D116. Nevertheless, similar to other polynucleotidyl transferases, a second metal can be most 
likely coordinated by E152 (with D64) once HIV-1 IN binds to its DNA substrate.
89
 CCD also 
encompasses a flexible loop comprising residues 140-149 known to be essential for 3’-P and 
ST reactions.
107
 Crystal structures of two domains constructs of HIV-1 IN that contain either 
the NTD-CCD (IN
1-212
) or CCD-CTD (IN
50-288
) have also been obtained.
108,109
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Figure 3.3. Structural domains of HIV-1 IN. (Top) N-terminal (IN
1–49
, left)
102
 (PDB code 1WJA), catalytic-core 
(IN
50–212
, middle)
106
 (PDB code 1BL3) and C-terminal (IN
219–270
, right)
103
 (PDB code 1IHW) domains; (Bottom) 
left, N-terminal/catalytic-core domain (IN
1–212
)
108
 (PDB code 1K6Y) and right, catalytic core/C-terminal fragment 
(IN
52–288
)
109
 (PDB code 1EX4). 
 
Despite the lack of detailed structural information of full-length IN, experimental studies 
are in agreement with an active multimeric protein. Time-resolved fluorescence anisotropy 
studies showed that a single IN dimer at each extremity of viral DNA molecules is required for 
3’-P.110 Cross-linking studies suggested that a tetrameric IN bound to the viral DNA ends is the 
complex involved in ST reaction.
111
 The recent X-ray crystal structure of IN from the prototype 
foamy virus (PFV-1 IN) in complex with its cognate viral DNA consists of an IN tetramer 
tightly associated with a pair of viral DNA ends.
101,112
 This complex is consistent with a low-
resolution structure obtained by electron microscopy and single-particle reconstruction for 
HIV-1 IN in complex with its cellular cofactor, the lens epithelium-derived growth factor.
113
 
 
 
 
 
 
 H   H   C   C 
12   16  40  43 
 D     D     E 
64   116  152 
Zn
2+
 binding 
Multimerization 
Mg
2+
 chelation 
Catalysis and DNA binding 
Non-specific  
DNA-binding 
1                                             50                                                                              212                                          288 
28│3   Focus on HIV-1 IN 
 
3.3. HIV-1 IN inhibitors 
 
Over the past decade of research, two strategies have been considered for the development 
of HIV-1 IN inhibitors (Figure 3.4). The first targets the free, unbound protein (IN DNA-
binding inhibitors or INBIs) whereas the second targets the complex resulting from the 
association of integrase with viral DNA (IN strand transfer inhibitors or INSTIs). More 
recently, another approach based on the inhibition of the interaction between HIV-1 IN and its 
cofactor LEDGF/p75 allowed to identify new leads in anti-IN drug design (LEDGINs). These 
three families of HIV-1 IN inhibitors are presented in this section.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Strategies used for the design of HIV-1 IN inhibitors. (Top) Crystal structure of HIV-1 CCD dimer 
(grey cartoon) (PDB code 2B4J)
114
 in complex with LEDGF/p75 (magenta cartoon) depicting the LEDGF/p75 IN 
binding domain (LEDGF/p75 IBD). (Left) Crystal structure of HIV-1 IN CCD (PDB code 1BL3)
106
 depicting the 
DNA-unbound form of the active site. (Right) Crystal structure of PFV-1 IN in complex with its cognate DNA 
substrate depicting the active site in DNA-bound form  (PDB code 3OY9)
112
. 
  
 3.3.1. IN DNA-binding inhibitors (INBIs) 
 
Styrylquinoline (Figure 3.5, compound a) and pyranodipyrimidine (Figure 3.5, 
compound b) derivatives represent two of the most important INBI series. They act on the 3’-P 
reaction in vitro by competing with viral DNA for binding to IN within the active site.
115,116
 
Further studies carried out with these compounds have revealed a multimodal mechanism of 
action. Indeed, it has been showed that styrylquinolines efficiently inhibit in vitro nuclear 
import of IN whereas pyranodipyrimidine block the viral entry.
117,118
 Random screening led to 
the discovery of a novel series of 1-pyrrolidineacetamides (Figure 3.5, compound c) which 
bind to specific residues in the HIV-1 IN CCD (K103, K173, and T174).119  
Inhibit DNA 
binding 
INBIs 
Inhibit LEDGF/p75 
interaction 
LEDGINs 
Inhibit  
enzyme-vDNA complex 
INSTIs 
Active site in DNA- 
unbound form 
LEDGF/p75 
LEDGF/p75 
IBD 
Active site in DNA-
bound form 
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Based on fluorescent stains (for labeling DNA) known to bind non-covalently and site-
specifically to the minor groove of DNA, other promising INBIs were developed. Specifically, 
the replacement of N-methylpiperazine rings by more hydrophilic N,N-dimethylaminopropyl 
carboxamide groups, combined with dimerization have led to identify an interesting bis-
benzimidazole derivative (Figure 3.5, compound d).
120
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Figure 3.5. Structures of most representative INBIs. 
  
3.3.2. IN strand transfer inhibitors (INSTIs) 
3.3.2.1. Development 
 
During a previous random large-scale screen, compounds with β-diketoacid (DKA) moiety 
were identified as potent HIV-1 IN inhibitors, presenting a significant preference for ST 
inhibition over 3’-P in vitro.121 The most active compounds of this study, L-731,988 and L-
708,906 (Figure 3.6) were the first INSTIs demonstrated to have antiviral activity directly as a 
consequence of their effect on HIV-1 integration. Simultaneously, other potent DKA 
containing aromatic indole rings and a tetrazole group in place of the common DKA carboxylic 
acid moiety were developed, leading to the first inhibitor co-crystallized with IN, 5-CITEP 
(Figure 3.6).
122
 X-ray crystal structure of the complex showed that 5-CITEP binds in the middle 
of the active site of the enzyme, lying between the three catalytic acidic residues, D64, D116 
and E152, in the vicinity of the active site metal ion. 
 
                                                     
* 
IC50: inhibitor concentration required to reduce enzymatic activity to 50 %.  
30│3   Focus on HIV-1 IN 
 
Further pharmacomodulations in the series of indole derivatives led to the inclusion of multiple 
nitrogen and oxygen-containing heterocycles. S-1360
123
 (Figure 3.6) was the first clinically 
tested inhibitor. Nevertheless, it failed clinical phase II due to its reduction in humans at the 
carbon linked to the triazole heterocycle, yielding an inactive metabolite that was rapidly 
cleared through glucuronidation in the non-cytochrome P450 pathway.
124
 
 
Structure-activity relationship (SAR) studies revealed the contributions of two common 
pharmacophoric features for ST inhibition and selectivity 
125
: (i) the sequestration of active site 
divalent metal ions by an aryl DKA chain (marked in bold) is critical for ST inhibition whereas 
(ii) an aromatic hydrophobic group (marked in dashed box) on a flexible tether at a relatively 
well-defined distance and angle from the metal binding center is crucial for potency and ST 
selectivity.  
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Figure 3.6. Structure of firstly developed β-diketoacid compounds with DKA moiety in bold.  
 
Due to the relevance of Mg-chelating functions for ST inhibition, isosteric replacements 
for the diketo acid pharmacophore have led to the rational design of new INSTIs classes 
(Figure 3.7).  
 
 
                                                     
* 
EC50: inhibitor concentration required to inhibit 50 % of HIV-1 replication. 
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 1,6 Naphtyridine carboxamide 
 
The substitution of the DKA pharmacophore with a 
naphthyridine carboxamide core led to the development of 
L-870,810
126
 (Figure 3.8), a 8-hydroxy-1,6-naphthyridine-
7-carboxamide derivative, showing very promising activity 
and becaming the second HIV-1 IN inhibitors to enter 
clinical trials. However, its significant human plasma 
protein binding brought a premature end to the drug's 
clinical progress.
127
 Various modifications at the 4-
Fluorobenzyl group were explored in order to decrease 
protein binding. 2-Amide analogue (Figure 3.8, compound 
a) had a lower percentage of protein binding than L-
870,810, good pharmacokinetic properties and is 
undergoing further preclinical development.
128
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Figure 3.8. Structures of the two most representative naphthyridine 
carboxamide derivatives. 
 
 
 Naphtyridinone 
 
In studies to develop follow-up analogs of S-1360, a 
joint research effort of scientists from Shionogi and 
GlaxoSmithKline exploited a new series of naphtyridinone. 
                                                     
* 
CI95 (NHS): concentration of inhibitor that reduce the spread of HIV-1 infection to 90% in the presence of 
normal human serum. 
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By combining optimal substituents at three positions (i.e., methyl group at N-1, N-(2-hydroxy) 
ethylcarboxamide at C-3, and 4-fluorobenzyl at C-7), GSK-364735
129,130
 (Figure 3.9), exhibiting 
antiviral potency and ST inhibition comparable to raltegravir and elvitegravir was developped. It 
demonstrated satisfactory results in a phase I clinical trial
131
, but its clinical development had 
been halted.  
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Figure 3.9. Structure of the naphtyridinone derivative GSK364735. 
 
 N-alkyl hydroxypyrimidone 
  
A previous screening of HCV polymerase inhibitors led to the identification of a new potent 
and selective class of INSTIs, the N-alkyl hydroxypyrimidones, having more drug-like 
properties than DKA compounds.
57,132-134
 Extensive SAR studies on the carboxamide moiety 
resulted to the identification of p-fluorobenzyl group as the optimal amide residue and dimethyl 
amino gem-dimethyl as the optimal 2-substituent (Figure 3.10, compound a). Further SAR 
studies were conducted to improve the activity against IN, focusing on the basic amine and the 
gem-dimethyl moieties. Substitution of the dimethyl amino group by acetamide functionality 
resulted in compound b (Figure 3.10) showing higher potency in both enzymatic and cell-based 
assays. The incorporation of aromatic and heteroaromatic amide as capping groups of the 
amine portion led to the identification of lead compounds with low nanomolar enzymatic and 
antiviral activities (Figure 3.10, compounds c, d and raltegravir). Further clinical development 
of raltegravir led to the first HIV-1 IN inhibitors approved by the FDA. This compound is 
included in current HAART regimen. 
 
 
                                                     
*
 EC90 (PBMC): inhibitor concentration required to inhibit 90 % of HIV-1 replication in peripheral blood  
mononuclear cell. 
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Figure 3.10.  Structures of N-alkyl hydroxypyrimidone class of compounds. 
 
 Tricyclic inhibitors 
  
In the aim to identify new INSTIs active towards raltegravir resistant mutants, 
pseudosymmetric tricyclic hydroxyl-pyridone carboxamides inhibitors were designed. The 
pseudo-symmetry is thought to contribute to multiple binding modes and as a result, escape 
from IN mutations. Optimization of this series led to the discovery of S/GSK1349572
68
 (Figure 
3.11), starting phase III clinical trials. This compound had a markedly different resistance 
profile as evidenced by limited cross-resistance to raltegravir resistant HIV strains. Keeping in 
mind the relevance to design new INSTIs with a high genetic barrier to resistance, new 
pyrazinopyrrolopyridazines derivatives were developed.
135
 The replacement of a pyridinone 
ring with a pyridazinone in original tricyclic hydroxypyrrole inhibitors resulted in higher 
oxidative stability of the hydroxypyrrole moiety. As a result, a lead compound, termed MK-
2048
136
 (Figure 3.11), exhibiting favorable pharmacokinetics and potent antiretroviral activity 
against four IN mutants displaying raltegravir resistance was identified. MK-2048 is still in pre-
clinical development. Based on the previously developed L-870,810, conformational constraint 
on the carboxamide carbonyl by cyclization led to a new class of pyrrolloquinolone inhibitors. 
Various C-5 substitutions in the pyrrolloquinolone core by amino derivatives resulted in a lead 
compound, GS-9160 (Figure 3.11), showing low nanomolar potency.
137,138
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The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily 
dosing was not likely to achieve antiviral efficacy. Consequently, the clinical development of 
this compound was discontinued.
139
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Figure 3.11. Structures of the three most representative tricyclic inhibitors. 
  
 4-oxo quinolone 
 
Based on the core structure of quinolone antibiotics, a novel class of quinolone 3-carboxylic 
acids containing a coplanar arrangement of a ketone and a carboxylic acid moiety was 
developed. In order to understand the SAR, various modifications were introduced at the N-1 
and C-6 positions on the 4-quinolone-3-glyoxlic acid scaffold (Figure 3.12, compound a).
64,65
 
Introduction of 2’-fluoro-3’-chloro substituents into the distal benzene ring and a hydroxyethyl 
group at the 1-position of the quinolone ring led to a significant improvement of ST inhibition 
and antiviral activity (Figure 3.12, compound b). Substitution at the 7-position with a methoxy 
group resulted in the higher potent compound c (Figure 3.12). Finally, introduction of an 
isopropyl group at the 1S-position of the hydroxyethyl moiety led to elvitegravir, the next 
promising HIV-1 IN inhibitors currently in phase III clinical trials.
140
 
 
Quinolonyl diketo acid derivatives have also been explored for their anti-IN activity.
141,142
 
These compounds contain the two pharmacophoric features essential for ST, i.e., a diketoacid 
chain and a p-F-benzyl group at 3- and 1-position of the quinolone scaffold (Figure 3.12, 
compounds d-k). SAR studies showed that the introduction of halogen atom in the quinolone 
ring resulted in inhibitory activity similar to that of the unsubstituted compound. The anti-IN 
activities appear to be influenced by the position of the halogen in the quinolone ring. A 1-
pyrrolidinyl substitution at position 7 decreased IN inhibitory potency but improved the 
antiviral activity. 
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Figure 3.12. Structures of quinolone 3-carboxylic acid (a-c, elvitegravir) and Quinolinonyl diketoacid inhibitors 
(d-k). 
 
3.3.2.2. Mode of action 
 
Crystallographic structure of inhibitors bound to the HIV IN-viral DNA complex continues 
to be a significant challenge. Consequently, the mechanism of action of INSTIs remains 
unclear. Based on biochemical data, it is hypothesized that INSTIs act as “interfacial 
inhibitors” by binding at the IN/DNA interface and coordinating one or two catalytic 
magnesium ions in a pocket flanked by the end of the viral LTR.143-145 This speculative 
mechanism of action tends to be validated by the recent X-ray crystal structure of PFV-1 IN in 
complex with its cognate viral DNA and INSTIs (Figure 3.13a-d).
112,146
  
6 3 
3 6 
1 
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These structures revealed a two-metal ion mechanism of action involving the coordination of 
the two metal cofactors within the active site by the common metal-coordinating 
pharmacophore of the INSTIs (Figure 3.13c). This interaction with the two Mg
2+
 ions resulted 
in the displacement of the terminal 3′ adenosine (Figure 3.13b) and the fit of the halobenzene 
groups into a pocket created by displacement of the terminal 3′ adenosine (Figure 3.13d). In 
this way, the inhibitor would probably prevent the attack of the viral 3′-end on a target DNA 
phosphodiester bond.  
 
                      
     
 
  
 
 
 
 
 
 
 
 
Figure 3.13. Crystal structure of PFV IN/DNA complex in its active and INSTI inhibited form. Mn
2+
 and Mg
2+
 
ions are shown as purple and green sphere, respectively. Protein is represented as grey cartoon whereas DNA and 
INSTIs are shown as orange and yellow sticks, respectively. a) PFV IN/DNA complex in its active Mn
2+
-bound 
form (PDB code 3OY9)
112
. b) Superimposition of Mg
2+
/INSTIs-bound PFV active site (PDB code 
3L2U/3OYA/3OYB/3OYD/3OYF)
112,146
 highlighting the two-metal ion mechanism of action of INSTIs. c) and d) 
Alternative views showing the displacement of terminal 3′ adenosine from the active site and the fitting of 
halobenzyl groups into the newly formed pocket.  
 
3.3.3.  Inhibitors of LEDGF/p75-IN interaction (LEDGINs) 
 
LEDGF/p75 is a cellular cofactor of HIV-1 IN that promotes viral integration by shifting 
IN oligomerization towards tetrameric structures and tethering the preintegration complex to 
the chromatin.
147
 Based on LEDGF/p75 functions, peptide LEDGF/p75 402-411 has been 
designed to shift IN towards tetrameric structures which do not catalyze 3’-P reaction requiring 
dimeric structures. This one inhibits both 3’-P and ST reactions with IC50 values below 21 µM. 
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Moreover, it was non-toxic in cell-based assays.
148
 Disrupting the interaction between IN and 
LEDGF/p75 by small molecules has recently been recognized as a potential therapeutic 
strategy. As revealed by crystal structure of HIV-1 IN CCD-LEDGF/p75 complex, 
LEDGF/p75 forms a specific interaction into a HIV-IN binding pocket at the interface of two 
monomers
114
. More specifically, four relevant amino acid residues Ile365, Asp366, Phe406 and 
Val408 are considered essential for the direct contact with HIV-1 IN CCD residues. On this 
basis, various small molecules with IC50s in the low micromolar range mimicking Asp366 
residues have been designed (Figure 3.14).
149-151
 Crystal structure of HIV-1 IN CCD in 
complex with compound c showed that the inhibitor occupied the same space in the binding 
pocket that LEDGF/p75, confirming an allosteric inhibition of HIV-1 IN.
149
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Figure 3.14. Chemical structures of IN-LEDGF/p75 interaction inhibitors.
                                                     
 
*
 Kd: equilibrium dissociation constant. 
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HIV-1 IN is an attractive and validated target for the development of novel therapeutics 
against AIDS. Over the last past decade, extensive research focusing on the ligand-based drug 
design approach have led to the identification of a plethora of INSTIs. Due to the lack of 
detailed structural information concerning HIV-1 IN/DNA-INSTI ternary complex, structure- 
based inhibitor design selective for IN/DNA complex has not kept pace. A more detailed 
understanding of INSTIs binding mode could lead to the design of more potent inhibitors with 
a higher genetic barrier against the emergence of resistant mutants. 
 
This thesis is in line with a project (WALEO 2 Program, ANTISIDA 2 Project, 
515995/616295) initiated together with the University of Namur (FUNDP, Chemistry 
Department) and Brussels (ULB, campus Gosselies, Laboratoire de virologie moleculaire) 
aiming at the design of HIV-1 IN inhibitors. The major goal of this work was to study the 
inhibition mechanism of HIV-1 IN by quinolone compounds combining experimental and 
theoretical approaches with a view to provide new insights into the mechanism of action 
of INSTIs. 
 
Previously, DKA derivatives containing the quinolinone scaffold have been reported as 
potential HIV-1 IN inhibitors.
141,142
 Based on this series, new compounds substituted at C-6 
with various substituents were synthesized in collaboration with Pr. Laszo Hevesi (FUNDP, 
Chemistry Department) (Figure 1).  
 
N
O
R6
O OH
OX
O
F
 X = Et, H
 R6 = Br, O-CH2(4'-F-Ph), HC=CHCOOEt(H)
 
Figure 1. Structure of 6-substituted quinolone compounds synthesized. 
 
All these compounds were evaluated for their anti-integrase and antiviral activity and 
SARs were established. The enzyme required for the evaluation of anti-integrase activity was 
expressed, purified and tested for its enzymatic activity. IC50 and EC50 values of quinolone 
compounds were then evaluated in in vitro and cell-based assays. All biological assays were 
performed in collaboration with the laboratory of Pr. Carine Van Lint (Laboratoire virologie 
moléculaire, ULB) and Dr. Jean-François Mouscadet (LBPA, ENS Cachan). 
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Otherwise, HIV-1 IN CCD expression and purification experiments were performed with a 
view to obtain a crystal structure of the enzyme in complex with short oligonucleotide substrate 
and/or quinolone compounds. 
 
In parallel, we studied the interaction between HIV-1 IN and quinolone compounds 
considering partners (DNA, Mg
2+
, water molecules) present during ST reaction. 
Physicochemical studies were performed to identify stable conformations as well as to 
investigate magnesium-chelating properties of quinolone compounds. Based on the very recent 
crystal structures of PFV-IN in complex with its cognate DNA substrate and INSTIs, a new 
HIV-1 IN/DNA theoretical model was also built. This model was used for docking studies to 
both predict the binding mode of quinolone compounds within HIV-1 IN/DNA complex and 
rationalize the observed SARs. Based on these results, a detailed mechanism of inhibition for 
quinolonyl DKA compounds was proposed. 
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1   Biochemical characterization of the inhibition of HIV-1 IN by 
quinolones 
 
 The establishment of SAR is an essential step to identify ligands stereoelectronics 
requirements essential for the interaction with their target enzyme. In this chapter, we planned 
to explore the effect of chemical modifications at position 6 of the quinolone scaffold by 
synthesizing new compounds containing at position C-6 an halogen atom or bulky hydrophilic 
and hydrophobic substituents (Figure 1.1). These compounds were synthesized in collaboration 
with the group of Laszlo Hevesi. To evaluate the anti-integrase activity of quinolone 
compounds, wild-type HIV-1 IN was expressed and purified. The activity of the produced 
enzyme was evaluated and IC50 values of quinolone compounds were determined in in vitro 
inhibition assays. Antiviral activities of these compounds were also evaluated by the laboratory 
of Pr. Carine Van Lint (Laboratoire virologie moléculaire, ULB). 
 
N
O
R6
O OH
OX
O
F
1a: X = Et; R6 = Br
1b: X = Et; R6 = O-CH2(4'-F-Ph)
1c: X = Et; R6 = HC=CHCOOEt
2a: X = H; R6 = Br
2b: X = H; R6 = O-CH2(4'-F-Ph)
2c: X = H; R6 = HC=CHCOOH
 
 
Figure 1.1. Structure of 6-substituted quinolone compounds synthesized. 
 
1.1. Synthesis of quinolonyl diketo ester and acid compounds   
 
The title compounds 1a-c and 2a-c were synthesized according to Di Santo’s 
procedure
141,142
 with modifications as presented in Scheme 1. The key intermediates 3-acetyl-
4(1H)-quinolinones (4a,b) were obtained by reaction of the appropriate aniline with ethyl 
ethoxymethyleneacetoacetate, followed by thermic cyclization in diphenyl ether. Then, 4a,b 
were alkylated with 4-fluorobenzylbromide in alkaline medium (K2CO3) to give compounds 
5a,b. Acrylate derivative 5c was obtained by palladium-catalyzed Heck reaction of 5a with 
acrylic acid ethyl ester. Compounds 5a-c was condensed with diethyl oxalate in the presence of 
sodium ethoxide to afford diketo esters derivatives 1a-c, which were in turn hydrolyzed by 
saponification reaction to give DKA derivatives 2a-c.  
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Scheme 1
a
. General synthetic pathway for the synthesis of quinolonyl diketo ester and acid derivatives (1a-c, 2a-
c). 
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R6 = Br, OH
3a R6 = Br (62 %)
3b R6 = OH (55 %)
4a R6 = Br (74 %)
4b R6 = OH (46 %)
5a R6 = Br (85 %)
5b R6 = OH (73 %)
R6
N
O O
F
5c R6 = CHCHCOOEt (62 %)
f,g
1a (83 %)
1b (82 %)
1c (79 %)
2a (73 %)
2b (79 %)
2c (70 %)
e
e
 
 
a 
Reagents and conditions: (a) ethyl ethoxymethyleneacetoacetate, 120 °C, 5 min; (b) Ph2O, reflux 40 min; (c) 4-
fluorobenzyl bromide, K2CO3, DMF, 100°C, 2 h; (d) Pd(OAc)2 cat., PPh3, NEt3, acrylic acid ethyl ester, DMF, 
80°C, 48 h; (e) diethyl oxalate, C2H5ONa, THF, 20 h, HCl, rt; (f) 1 N NaOH, THF/MeOH (1:1), 1.15 h; (g) HCl 
1N, rt.  
 
1.2. His-tagged wild-type HIV-1 IN preparation 
 
 Full-length wild-type HIV-1 IN is known to be an insoluble protein with very poor stability 
at room temperature. Consequently, enzyme preparation required stringent conditions (t°c, pH, 
ionic strength ...) to purify in its native form. All attempts performed in our laboratory did not 
allow to produce active IN. For this reason, enzyme preparation was performed within the 
laboratory of Dr. J.-F. Mouscadet (LBPA, ENS Cachan).
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 1.2.1. Expression in BL21(DE3)pLysS 
 
 pET-15b-IN plasmid encoding for His-tagged wild-type HIV-1 IN (HT-wt-IN
1-288
) was a 
generous gift of R. Craigie (NIH, AIDS Research and Reference Reagent Program, USA). It 
contains a T7 promoter just upstream of the protein-coding region, regulating its expression and 
an ampicillin resistance gene used as a selectable marker (Figure 1.2). In this system, the 
interest protein is produced when bacterial T7 RNA polymerase binds to T7 promoter. In 
normal conditions, T7 RNA polymerase is not or very weakly produced. The addition of 
isopropyl-β-D-galactoside (IPTG) induces the expression of T7 RNA polymerase and 
consequently, the interest protein. 
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Figure 1.2. pET-15b-IN plasmid encoding for HT-wt-IN
1-288
.  
 
 HT-wt-IN
1-288
 was expressed in E. coli BL21(DE3)pLysS competent cells. These ones 
contain the pLysS plasmid expressing T7 lysozyme that suppresses basal expression of T7 
RNA polymerase prior induction toxic for cells. After bacterial protein expression by IPTG 
induction, crude lysate obtained by cells lysis were centrifuged in the aim to obtain the interest 
protein in the supernatant and other bacterial proteins and cellular debris in pellets. To verify 
the expression level of IN protein, the crude lysate, supernatant and pellets were analyzed by 
SDS/PAGE (Figure 1.3). Whole analyzed fractions showed induced IN of the predicted size 
(32 kDa) that migrated just below the 37 kDa molecular size marker. Although a large part of 
insoluble enzyme was retained in pellet, HIV-1 IN was recovered as a soluble protein in the 
supernatant in reasonable quantity. 
 
 
 
Figure 1.3. Coomassie stained SDS/PAGE analysis of Wild-type HIV-1 IN expression. The arrow indicates the 
position of His-tagged IN. Lane 1 = molecular size marker, lane 2 = lysate, lane 3 = pellet and lane 4 = 
supernatant. 
 
 1.2.2. Purification by affinity chromatography 
 
 The presence of an His-tag at the N-terminus of the protein of interest allowed purification 
by affinity chromatography (Ni
2+
) of the supernatant containing HT-wt-IN
1-288
.  
 
pET-15b-IN 
His6 -Tag 
HT wt IN
1-288
 
T7 promoter 
Amp
R
 
37 kDa 
  1.      2.       3.      4. 
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His-tagged proteins having an affinity for nickel ions immobilized on nitrilotriacetic acid-
agarose (NTA) resin are retained whereas other proteins and contaminants which don’t have 
affinity for nickel ions are directly eliminated. Finally, proteins specifically fixed on Ni-NTA 
resin are eluted with imidazole.  
 
 Due to the poor enzyme stability at room temperature, purification procedure was adapted 
to keep protein extracts on ice. In this procedure, his-tagged enzyme bounded to Ni-NTA 
agarose beads was purified and eluted by washing beads with buffer A containing growing 
imidazole concentrations (from 0 to 1M). At each step of the procedure, protein supernatants 
were isolated from beads by gravity settling on ice. SDS/PAGE analysis of the different 
fractions corresponding to beads and proteins supernatants from washes and elution is 
represented at figure 1.4. A large part of protein contaminants having not or low affinity for Ni-
NTA beads were eluted with 0 and 80 mM of imidazole (Figure 1.4, lane 4-7). As a result, the 
elution of the His-tagged enzyme with 1M imidazole (Figure 1.4, lane 8) gave a band just 
below the 30 kDa molecular size marker with other contaminants bands. Finally, purified IN 
was dialyzed in dialysis buffer to obtain a precipitated enzyme which was dosed using the 
Bradford method. Global yield was about 9 ml of purified enzyme at 0.7 mg/ml from 700 ml of 
culture medium. 
 
 
 
Figure 1.4. Coomassie stained SDS/PAGE analysis of HT-wt-IN
1-288 
purification profile. The arrow indicates the 
position of His-tagged IN. Lane 1 = molecular size marker, lane 2 = lysate, lane 3 = supernatant of crude E. coli, 
lane 4 and 5 = supernatant and beads after overnight incubation with Ni-NTA agarose, lane 6 and 7 = beads after 
washing with tampon containing 0 and 80 mM imidazole, lane 8 = elution product with 1 M imidazole, Lane 9 = 
protein after dialyzis.  
 
 1.2.3. Western-blot analysis 
 
 Identity of purified IN was validated by Western blot analysis using HIV-1 IN specific 
antibodies. The precipitated protein obtained after dialysis was first subjected to SDS-PAGE 
(Figure 1.5 left) and then transferred to nitrocellulose membrane. As shown by antibodies 
revelation (Figure 1.5 right), the major band just above 30 kDa corresponded to HT-wt-IN
1-288
. 
The other bands revealed at higher molecular weight could correspond to aggregated proteins. 
30 kDa 
        1.     2.      3.      4.      5.      6.      7.      8.      9. 
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Figure 1.5. (Left) Coomassie stained SDS/PAGE of precipitated wild-type HIV-1 IN. Lane 1 = molecular size 
marker, lane 2 = dialyzed IN. (Right) Western blot analysis of proteins separated by SDS-PAGE using HIV-1 IN 
specific antibodies. 
 
1.3. Biological assays 
 
 All biological assays were performed within the laboratory of Pr. Carine Van Lint 
following protocol optimized by the laboratory of Dr. J.-F. Mouscadet (LBPA, ENS Cachan).
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 1.3.1. Catalytic properties of purified recombinant IN 
 1.3.1.1. Radioactive gel-based assay 
 
Purified IN was evaluated for its 3’-P and ST activity using a radioactive gel-based assay 
(Figure 1.6). Olignonucleotides (21 mers) derived from U5LTR extremity of viral DNA were 
radiomarked at 5’end with 32P. Following 3’-P reaction, HIV-1 IN cleaves a dinucleotide at 3’-
end extremity, giving 19-mer oligonucleotide which constitutes the substrate for ST reaction 
(Figure 1.6a). Indeed, this later is integrated in other strands, leading to 19 + n multimeric 
oligonucleotides (Figure 1.6b). All these enzymatic reaction products were finally separated on 
acrylamide/urea gel which was exposed to a PhosphorImager screen absorbing radioactive 
emission. As a result, specific bands corresponding to 3’-P and ST activity of HIV-1 IN were 
quantified with ImageQuant software.  
 
                                                                        
Figure 1.6. Principle of the radioactive gel-based assay used for the evaluation of HIV-1 IN 3’-P and ST activities. 
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A range of enzyme concentrations (from 50 to 800 nM) was tested to determine the 
optimum enzyme concentration for in vitro inhibition assays (Figure 1.7). The purified enzyme 
showed optimum 3’-P and ST activity at 400 and 800 nM. 
 
 
 
                                             
 
Figure 1.7. Phosphorimager picture showing enzymatic activities for various IN concentrations. C
-
 corresponds to 
EDTA-inactivated enzyme.  
 
 1.3.1.2. Colorimetric assay 
  
Enzymatic activity of purified IN was also evaluated in a more rapid and easy-to-use 
colorimetric assay (Figure 1.8).  
 
                                                      
 
 
 
 
Figure 1.8. Principle of colorimetric assay evaluating ST activity of HIV-1 IN. 
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In this assay, ST activity of HIV-1 IN is evaluated by using a 5’-biotin labeled pre-processed 
19-mer oligonucleotides as substrate and a 3’-digoxygenin labeled oligonucleotides as target. 
Following ST reaction, biotinylated substrate is inserted into digoxinylated target to form 
oligonucleotide products marked at the two extremities. These latter are then coated on 
streptavidine plate due to the specific interaction between biotin and streptavidine. Anti-
digoxygenin antibodies (horseradish peroxidase conjugated) are added to the well and revealed 
with chromogenic substrate (ABTS) at 405 nm. 
 
The two optimal IN concentrations determined by radioactive experiment (400 and 800 
nM) were tested (Figure 1.9). Data obtained showed that these two enzyme concentrations 
showed significant ST activity, with an absorbance at 405 nm 3 and 5 fold higher than that of 
the negative control (EDTA-inactivated enzyme). Nevertheless, high variability in absorbance 
measurement was observed, with standard deviation of 0.24 and 0.21. As a consequence, this 
test was not used in subsequent inhibition assays. 
 
 
Figure 1.9. ST activity of HT wt IN
1-288
 detected in colorimetric assay by measurement of the absorbance at 405 
nm. 
 
 1.3.2. Biological evaluation of quinolone compounds 
 
Diketo ester and acid derivatives 1a-c and 2a-c were tested for their ability to inhibit 3’-P 
and ST reactions in radioactive gel-based assay. IN was used at 400 nM because this 
concentration allowed to have a good level of activity without consuming too much protein. 
IC50 values were calculated using dose response curves (Table 1). As already observed for 
quinolonyl DKA series
141,142
, acidic derivatives were more potent than the corresponding 
esters, with a high selectivity against ST. The replacement of a bromine atom at C-6 by an 
anionic (acrylate) or a hydrophobic (4-fluoro-benzyloxy) group did not lead to a significant 
improvement of HIV-1 IN inhibition.  
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Indeed, compounds 2b and 2c showed IC50 values against ST (ST IC50= 0.03-0.05 µM) similar 
to the one of 6-bromide analogue 2a (ST IC50= 0.03 µM) with a moderate increase in the 
selectivity for ST versus 3’-P. These results suggest that the size of substituents at C-6 on the 
quinolone scaffold affects the ability of the inhibitor to discriminate between the active site of 
the DNA-bound or -unbound form of HIV-1 IN. Moreover, once the inhibitor is bound to the 
IN/DNA complex, substituents at C-6 do not make significant interaction.
152,153
 
 
The activity of the title quinolone compounds against wild-type HIV-1 was established by 
determining their ability to inhibit viral infection using TZM-bl cell lines.
38
 These cells are 
genetically engineered HeLa cell lines that express CD4, CXCR4 and CCR5 and contains -
Gal reporter genes encoding for β-galactosidase enzyme which is only expressed under the 
control of the HIV-1 LTR sequence. HIV-1 infection in cells is so evaluated by measuring β-
galactosidase activity using a colorimetric assay. The cytotoxicity was evaluated based on the 
cleavage of the tetrazolium salt by mitochondrial dehydrogenases in viable TZM-bl cells. 
Cytotoxicity (CC50) and antiviral activities (EC50) of compounds 1a-c and 2a-c are presented in 
Table 1. All tested compounds showed antiviral activity at non-cytotoxic concentrations. All 
derivatives were characterized by low cytotoxicity with CC50 values up to 1 mM. The antiviral 
activities are correlated with the anti-integrase activities. Indeed, acidic derivatives 2a-c were 
more potent than the corresponding esters 1a-c and showed similar EC50 values. Ester 
derivatives 1a and 1b were able to inhibit HIV-1 infection in cells with EC50 values of 17 and 
13 µM. This potential inhibitory activity could be explained by the presence of hydrolases in 
the cytoplasm of the cells which could partly convert ester compounds into active acidic 
compounds. Compared to 1a and 1b, ester derivative 1c showed lower inhibitory potency 
against HIV-1 with EC50 value up to 140 µM, suggesting a weaker hydrolyzed fraction of the 
compound in cells. 
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Table 1. Cytotoxicity, antiviral and anti-integrase activities of diketo ester and acid derivatives 1a-c and 2a-c. 
 
N
O
R6
O OH
OX
O
F  
 
Compd R X 
anti-IN activity, IC50
a 
 antiviral activity 
3’-P ST EC50
b
 CC50
c
 
1a Br Et 78 0.12  17 > 1000 
1b 
 
O-CH2-4-F-Ph Et > 300 > 300  13 > 1000 
1c HC=CHCOOEt Et > 300 > 300  > 140 > 1000 
2a Br H 1.6 0.03  4 > 1000 
2b O-CH2-4-F-Ph H 3 0.05  1 > 1000 
2c HC=CHCOOH H 8 0.03  5 > 1000 
  a 
Inhibitory concentration 50 % (µM) determined from dose response curves. 
b
 Ex vivo anti-HIV activity (µM)                                                                                               
(TZM-bl cells). 
c
 Cytotoxic concentration 50 % (µM) (TZM-bl cells). 
 
1.4. Conclusion 
 
This first chapter was focused on the biological evaluation of 6-substitued quinolone 
compounds as potential HIV-1 IN inhibitors. These synthesized compounds showed potent 
antiviral and anti-integrase activity, with a high selectivity for ST reaction. SAR studies 
established that acid compounds were more potent than corresponding esters whereas the 
introduction of both hydrophilic or hydrophobic substituents at C-6 did not have any effect on 
the activity in comparison with the activity observed with bromine derivative.  
 
In term of these results, it appeared clear that these compounds interacted specifically with 
the DNA-bound form of HIV-1 IN. The study of the interaction of quinolone compounds 
within such complex was so essential to predict their binding mode. 
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2   Expression and purification of HIV-1 IN CCD  
 
 Prior efforts to crystallize full-length HIV-1 IN have been hampered by poor enzyme 
solubility. The mutation F185K markedly improved solubility of the central IN CCD, leading 
to the resolution of its crystal structure alone or in complex with an INSTI (5-CITEP).
122
 
Nevertheless, it is doubtful whether this structure represents the true binding mode when DNA 
substrate is present. The knowledge of a three-dimensional structure of HIV-1 IN CCD in 
complex with viral DNA and an INSTI would allow determining their binding mode.  
 
In this chapter, we report the production and purification attempts of HIV-1 IN CCD with a 
view to crystallize the enzyme with short oligonucleotide substrate and quinolone compounds. 
 
2.1. Expression of soluble His-tagged HIV-1 IN CCD in E. coli  
 
Plasmid encoding for soluble His-tagged HIV-1 IN CCD (HT-IN
50-212
 (F185K)) was a 
generous gift of R. Craigie (NIH, AIDS Research and Reference Reagent Program, USA). It 
contains an IPTG-inducible T7 promoter allowing the expression of the interest protein. HT-
IN
50-212
 (F185K) was expressed following protocol described in literature
154
 by transforming E. 
coli BL21(DE3)pLysS competent cells with pET-15b-IN plasmid. After IPTG induction, crude 
lysate obtained by cell lysis was centrifugated to give supernatant and pellet. Whole fractions 
analyzed by SDS/PAGE (Figure 2.1) showed induced enzyme of the predicted size (20 kDa) 
that migrated just below the 20 kDa molecular size marker. Although a part of insoluble 
enzyme was retrieved in pellet, HT-IN
50-212
 (F185K) was recovered as a soluble protein in 
supernatant. 
 
 
 
Figure 2.1. Coomassie stained SDS/PAGE analysis of HT-IN
50-212
 (F185K) expression. The arrow indicates 
the position of the enzyme. Lane 1 = molecular size marker, lane 2 = lysate, lane 3 = pellet and lane 4 = 
supernatant. 
 
20 kDa 
   1.    2.      3.    4. 
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2.2. Purification of HT-IN
50-212
 (F185K) 
 2.2.1. Nickel affinity chromatography 
 
 The presence of an His-tag at the N-terminus of the enzyme allowed first purification of 
HT-IN
50-212
 (F185K) by nickel affinity chromatography. Due to its higher solubility and 
stability compared to full-length enzyme, the recombinant truncated enzyme was purified using 
FPLC system. This automated liquid chromatography allowed to separate proteins through 
constant flow rate of solvents controlled by pumps and monitorated protein elution by 
measuring the absorbance at 280 nm. The chromatogram profile obtained and SDS/PAGE 
analysis of corresponding fractions are represented in figure 2.2. 
 
 
 
Fractions:                                             11                27            41                                    7’ → 16’ 
 
                                                        
 
Figure 2.2. Chromatogram profile (top) and SDS/PAGE analysis of corresponding fractions (bottom) obtained 
from nickel affinity chromatography of HT-IN
50-212
 (F185K). Molecular size marker and initial supernatant are 
shortened by M and S respectively. 
M   S   11   27   41 
 
M    S    7’  8’  9’  10’ 11’12’ 13’ 14’ 15’16’  
 
Supernatant loading 
Buffer A 
5 mM Imidazole Buffer A 
60 mM Imidazole 
Gradient 
60 mM → 1 M Imidazole 
20 kDa 20 kDa 
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 After passing the supernatant through Ni-NTA sepharose column, proteins which had no or 
low affinity for Ni-NTA matrix were directly eliminated by two washing steps with buffer A 
containing 5 and 60 mM imidazole (fractions 11, 27 and 41). The application of a 
linear imidazole gradient (60 mM to 1 M) gave two overlapped peaks corresponding to the 
elution of the His-tagged enzyme with other contaminants (fractions 7’ to 16’). The presence of 
these latter could be due to nonspecific binding of bacterial proteins to the Ni-NTA matrix.  
 
Fractions 7’ to 16’ containing purified enzyme were recolted, dialyzed against storage 
buffer and protein concentration was evaluated by measuring the absorbance at 280 nm 
(nanodrop). Global yield was about 30 ml of purified HT-IN
50-212
 (F185K) at 0.5 mg/ml for 800 
ml of culture medium. Finally, the enzyme was aliquoted and conserved at -80°C. 
 
At this stage, enzyme purity obtained was not sufficient to perform crystallographic assays. 
Before the investigation of other purification steps, we evaluated the enzymatic activity of 
purified HT-IN
50-212
 (F185K). 
 
 2.2.2. Evaluation of enzymatic activity 
 
 Purified HT-IN
50-212
 (F185K) was tested for its disintegration activity using a radioactive 
gel-based assay (Figure 2.3). Hairpin oligonucleotide substrate containing HIV-1 LTR 
sequence was radiomarked at 5’end with 32P. Disintegration reaction occurring precisely at the 
junction between the viral and the target DNA sequence is expected to form two products, i.e., 
a 14-nucleotide hairpin (14-n) and a 24-nucleotide circular molecule (24-n). After separation on 
acrylamide/urea gel and exposition to a PhosphorImager screen absorbing radioactive emission, 
only the radiomarked 14-nucleotide hairpin is observed. 
 
 A range of purified HT-IN
50-212
 (F185K) concentrations (from 100 to 1600 nM) were 
tested (figure 2.3 left) and active full-length IN previously prepared (see chapter 1 of results) 
was used as positive control (figure 2.3 right). As revealed by the presence of a radiomarked 
14-nucleotide hairpin, the purified enzyme was active and possessed like full-length IN 
optimum catalytic activity at 400 and 800 nM.  
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Figure 2.3 Catalytic disintegration of purified HT-IN
50-212
 (F185K) (left) and wild-type HIV-1 IN (right). C
-
 
corresponds to EDTA-inactivated enzyme. 
 
 2.2.3. Size-exclusion chromatography 
 
The presence of high molecular weight contaminants led us to purify HT-IN
50-212
 (F185K) 
by size exclusion chromatography (SEC) using ÄKTA automated liquid chromatography 
system. The separation of the sample molecules is achieved by the differential exclusion as 
they pass through a bed of porous particles. Molecules that are smaller than the pore size can 
enter the particles and therefore have a longer path and longer transit time than larger 
molecules that cannot enter the particles. This method allows the elution of proteins in reverse 
order of their molecular size. 
 
The protein was dialyzed against buffer at pH 7.5 and passed through sephadex column. 
The chromatogram profile obtained (Figure 2.4 top) showed two minor peaks completely 
overlapped by a major one. This profile could be explained by the presence in solution of 
different HT-IN
50-212
 (F185K) oligomerization state. Coomassie and silver stained SDS/PAGE 
(Figure 2.4 bottom) revealed that the major part of HT-IN
50-212
 (F185K) with high 
molecular weight contaminants were retrieved in fractions 17 corresponding to the major 
elution peak whereas very small quantities of pure enzyme were retrieved in fractions 24 to 34 
corresponding to the third minor peak. In other words, SEC did not allow to obtain sufficient 
amount of pure enzyme to perform crystallographic assays. 
 
HIV-1 CCD 
5’-32P 
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14-n  
24-n 
+ 
      1600  800  400   200   100     C-       C
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Fractions:                                             12             17                                 24 → 34  
 
                                     
 
Figure 2.4. (Top) Chromatogram profile obtained from SEC. (Bottom) Coomassie stained (left) and silver stained 
(right) SDS/PAGE of corresponding fractions. Molecular size marker and protein sample before purification are 
shortened by M and BP respectively. 
 
 2.2.4. Ion-exchange chromatography 
 
Parallel to SEC, other purification attempts were performed by ion exchange 
chromatography which separated proteins based on their charge. Separation depends upon the 
reversible adsorption of charged solute molecules to immobilized groups of opposite charge. 
These ionizable groups are charged positively (anion exchange) or negatively (cation 
exchange) and reversibly bound to exchangeable conter ions (Na
+
 or Cl
-
). Given the fact that 
the isoelectric point of HT-IN
50-212
 (F185K) is comprised between 7 and 8, the protein solution 
was adjusted at pH 9.5 and 6 for anion and cation exchange chromatography, respectively. 
 
  2.2.4.1. Anion-exchange chromatography 
 
In order to charge protein negatively and remove NaCl from the solution, protein sample 
was dialyzed against a buffer without NaCl at pH 9.5.  
    M   12   17   24   25    26    27    28    34    BP        M   12   17   24   25    26    27   28    34   BP     
20 kDa 20 kDa 
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After loading the protein sample onto the MonoQ column (GE Healthcare), a first wash buffer 
containing 0.25 M NaCl was applied to directly elute proteins which were not sufficiently 
charged to interact with the resin. Then, a linear gradient from 0 to 1 M NaCl was applied to 
elute proteins fixed to the resin.  
 
The chromatogram profile and SDS/PAGE analysis of corresponding fractions are 
represented in figure 2.5. The presence of the major part of HT-IN
50-212
 (F185K) with other 
protein contaminants in elution peak (fractions 3 to 6) indicated that the enzyme binds very 
weakly to the resin. Very small quantities of pure enzyme (only detected by silver stain) were 
eluted with linear gradient (fractions 6’ and 7’). 
 
 
 
 
Fractions:                1        2                    3 → 7                                               6’  7’  
 
                            
 
Figure 2.5. (Top) Chromatogram profile obtained from anion-exchange chromatography. (Bottom) Coomassie 
stained (left) and silver stained SDS/PAGE of corresponding fractions. Molecular size marker and protein sample 
before purification are shortened by M and BP respectively.  
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  2.2.4.2. Cation-exchange chromatography 
 
Protein sample was dialyzed against buffer at pH 6 to charge protein positively and remove 
NaCl from the solution. After loading the protein sample onto the SP column (GE Healthcare), 
buffer containing 0.25 M NaCl was applied to the column to elute weakly positively charged 
proteins. Then, a linear gradient from 0.25 to 1 M NaCl was applied to elute proteins fixed to 
the resin. The chromatogram profile and SDS/PAGE analysis of corresponding fractions are 
represented in figure 2.6. 
 
 
 
 
Fractions:                                               6                                             15’  16’                  18’      21’ → 24’                                                
 
                              
 
Figure 2.6. (Top) Chromatogram profile obtained from cation-exchange chromatograph. (Bottom) Coomassie 
stained (left) and silver stained (right) SDS/PAGE of corresponding fractions. Molecular size marker and protein 
sample before purification are shortened by M and BP respectively.  
 
Interestingly, contaminants proteins are directly eliminated from the column (fraction 6) 
whereas HT-IN
50-212
 (F185K) was eluted during NaCl gradient (fractions 15’ to 24’). 
Buffer 
0.25 M NaCl 
Gradient 
0.25 M → 1 M NaCl 
 M    6    BP  15’ 16’  18’  21’  22’   23’  24’  
20 kDa 
 M    6    BP  15’ 16’  18’  21’  22’   23’  24’  
20 kDa 
62│2   Expression and purification of HIV-1 IN CCD 
Indeed, fractions 18’ to 22’ corresponding to the first and second eluted peak contained highly 
pure enzyme. However, the slow elution of the enzyme resulted in high dilution as well as 
considerable lack in fractions containing other contaminants (fractions 15’, 16’ and 23’, 24’).  
 
2.3. Thrombin cleavage of HT-IN
50-212
 (F185K)  
 
All crystallographic studies of HIV-1 IN CCD described to date report the removal of the 
hexahistidine tag from the recombinant protein. A thrombin cleavage site (Leu-Val-Pro-Arg-
Gly-Ser) was included in linker regions of the recombinant fusion protein construct. Thrombin 
can be used to selectively cleave between the Arginine and Glycine residues of the cleavage 
site, effectively removing the purification tag from the protein of interest with a high degree of 
specificity.  
 
 Due to the low amount of pure enzyme obtained by SEC and ion-exchange 
chromatography, we decided to investigate His-tag cleavage by incubating 1 mg of purified 
protein after IMAC with thrombin protease. To determine optimum cleavage conditions, 
fractions corresponding at different incubation times (20 min to 60 min) were analyzed by 
SDS/PAGE (Figure 2.7). The presence of a smaller molecular size band just below that 
corresponding to HT-IN
50-212
 (F185K) after thrombin addition highlighted partial cleavage of 
His-tag. As revealed by the intensity of the band corresponding to non-cleaved protein, 
maximum cleavage occurred in the first 20 minutes. 
 
 
 
 
 
Figure 2.7. Coomassie stained SDS/PAGE analysis of HT-IN
50-212
 (F185K) thrombin cleavage assay. Molecular 
size marker and protein sample before thrombin cleavage are shortened by M and BC, respectively.  
 
 Non-cleaved protein was removed by passing protein sample through a nickel affinity column by 
following the same procedure than for HT-IN
50-212
 (F185K) purification with minor modifications. 
The chromatogram profile and silver stained SDS/PAGE analysis of corresponding fractions 
indicated that purification process allowed to separate cleaved protein from non-cleaved protein 
(Figure 2.8).  
  M   BC     20      40      60     
min 
20 kDa 
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Indeed, an unique band corresponding to cleaved protein was retrieved after washing the 
column with buffer A containing 20 and 60 mM imidazole (fractions 19, 25, 26), highlighting 
the non-specific affinity of cleaved enzyme for Ni-NTA resin. 
 
 
Fractions:                                                5 → 12                                      19                      25  26               34  
 
 
 
Figure 2.8. (Top) Chromatogram profile obtained from nickel affinity chromatography of protein sample after 
thrombin cleavage. (Bottom) Silver stained SDS/PAGE analysis of corresponding fractions. Molecular size 
marker, protein sample before cleavage and after cleavage are shortened by M, BC and AC respectively. 
 
 After affinity purification, it should be relevant to check the presence of thrombin protease 
in protein sample and remove it on benzamidine sepharose. This resin contains a covalently 
attached synthetic trypsin-like serine protease inhibitor (p-aminobenzamidine) allowing 
specific interaction with thrombin protease. Then, further protein purification could be 
performed with a view of its crystallization. 
 
 
 
 
 M  BC  AC    5     6     8    11   12   19  25   26   34   
20 kDa 
Loading 
Buffer A 
5 mM Imidazole 
Buffer A 
20 mM Imidazole 
Gradient 
60 mM → 1 M Imidazole 
Buffer A 
60 mM Imidazole 
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2.4. Conclusion 
 
At the term of this experimental work, different conditions were tested to obtain pure and 
active HIV-1 IN CCD essential to perform crystallographic assays. Protein expression in 
BL21(DE3)pLysS followed by a nickel affinity chromatography allowed to obtain a good level 
of active enzyme. Other purification attempts were investigated to increase enzyme purity. SEC 
and ion-exchange chromatography did not allow to obtain sufficient amount of pure enzyme. 
His-tag cleavage with thrombin followed by a nickel affinity chromatography gave cleaved 
protein which could be purified. 
 
At this stage, it is clear that optimizations should have been done to obtain pure cleaved 
protein to perform crystallographic assays. The inherent difficulty in protein crystallization as 
well as the publication of crystal structures of PFV IN in complex with both DNA and 
INSTIs
112,146
 led us to focus our research towards the determination of quinolone compounds 
binding mode using physicochemical and molecular modeling studies. 
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3   Study of the interaction between quinolone compounds and 
HIV-1 IN/DNA complex 
 
As mentioned in chapter 1, the determination of the binding mode of quinolone compounds 
required to study their interaction with HIV-1 IN considering different partners (DNA 
substrate, Mg
2+
 ions and water molecules) involved in ST reaction.  
 
In this chapter, physicochemical studies of selected quinolone compounds were performed 
in order to identify the most stable conformations of those quinolone derivatives as well as the 
magnesium-chelating properties of their diketoacid moiety. In addition, a new HIV-1 IN/DNA 
model was built and docking studies were performed to predict the binding mode of 
synthesized quinolone compounds and to rationalize the observed SARs. Based on these 
results, a detailed mechanism of inhibition for quinolonyl DKA compounds was proposed.  
  
3.1. Physicochemical characterization  
 3.1.1. Crystal structure analysis of 6-bromide derivative 
 
Crystal structure determination of 2a and the different intra and intermolecular interactions 
stabilizing crystal packing are represented in figure 3.1 and table 1, respectively. Quinolone 
compound 2a cocrystallized with DMSO, both molecules being linked by hydrogen bonds 
between carboxylic acid group and DMSO oxygen O33a. The DKA chain and the quinolinone 
ring of compound 2a are nearly coplanar with torsion angle (T1) C4-C3-C18-O25 of 177°. The 
orientation of the diketo moiety with respect to the quinolinone ring is governed by 
intramolecular C2-H2---O25 and C19-H19---O26 hydrogen bonds. In this solid-state structure, the 
equilibrium between β-diketo and keto enol forms is displaced in favour of the keto-enol 
isomer, the hydrogens on C19 and O25 being clearly identified by Fourier difference. However, 
it is difficult to discriminate between the two potential keto-enol tautomers. Indeed, H25 is 
involved in a strong hydrogen bond with O24 and the O25-H25 distance (1.06 Å) is greater than 
commonly observed for O-H bonds (0.82 Å). Furthermore, both carbonyl (C18-O25 and C20-O24) 
and  carbon-carbon (C18-C19 and C19-C20) bond distances are similar and intermediate between 
standard single and double bonds, indicative of strong electronic delocalization within this 
keto-enol moiety. 
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In the crystal packing, π-π stacking interactions between quinolone rings (centroid-centroid 
distances of 3.6 Å) are observed and could influence the binding to the enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. (Left) Crystal structure (ORTEP) of compound 2a (cocrystallized with DMSO) showing the atom-
numbering and hydrogen-bonding scheme. Displacement ellipsoids are drawn at the 30% level.
155
 (Right) Crystal 
packing representation  revealing π-π stacking interactions between quinolone ring. 
 
Table 1. Intra and intermolecular interactions involved in crystal structure (symetry #1: 2-x,-y,1-z ; symetry #2: 
1+x, y, z). H bonds between acceptors A and donors D-H are characterized by a distance 1 D-A, a distance 2 
H…A and an angle D-H…A. π-π stacking interactions are characterized by a distance 1 between centroids. 
 
interactions partners distance 1 (Å) distance 2 (Å) angle (°)  
 
H bonds 
 
O25-H…O24 
 
2,467(6) 
 
1,520  
 
145 
 
O22-H…O33#1  
 
2,519(10) 
 
1,710  
 
120 
C-H…O 
interactions 
 
C19-H…O26  
 
2,912(7) 
 
2,290  
 
124 
 
π-π stacking 
 
Cycles I-II
#2 
 
3,659(4) 
 
- 
 
- 
 
 
 3.1.2. Solution-state conformation analysis  
 
 Solid-state XRD study allowed to identify a stable conformation of neutral compound 2a. 
Nevertheless, under physiological conditions, the DKA chain is unprotonated.
143,156
 Based on 
these considerations, the solution-state conformation of dianionic compound 2a was 
investigated using UV-visible spectroscopy and theoretical calculation considering bulk solvent 
effects.
157
 
DMSO 
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 First of all, geometries optimization and simulation of UV-visible absorption spectrum of 
neutral compound 2a was investigated to validate the chosen theoretical approach. The most 
stable geometry obtained at PCM-PBE0/6-311G(d,p) level of theory can be straightforwardly 
compared to the experimental XRD data (Figure 3.2 left). We noted that the PBE0 and XRD 
orientation of the DKA side chain completely matched (the C2-C3-C18-C19 torsion angle being 
close to 180° in both cases), as well as on the enol nature of this chain. The same agreement 
holds for the relative positions of the p-F-benzyle and central quinolone rings, with a twist 
angle of -51° by XRD and -55° with DFT. Moreover, theoretical electronic transition obtained 
at PCM-PBE0/6-311+G(2d,p) level of theory for the most stable conformation of neutral 
compound 2a was in agreement with experiment, with two predicted absorption bands at 382 
nm and 303 nm, close to the measured values (Figure 3.2 right). The first absorption (382 nm) 
corresponds to a HOMO to LUMO electronic transition, whereas the second peak (303 nm) 
presents an HOMO-2 to LUMO character with a smaller HOMO to LUMO + 1 contribution. 
The topologies of these frontier orbitals are sketched in Figure 3.3. The HOMO is mainly 
centered on the quinolone rings, the LUMO being located on the lateral chain. Therefore the 
first transition implies an electron transfer from the quinolone to the diketo side chain. For the 
second transition, the amplitude of the charge-transfer is obviously reduced. The chosen 
theoretical approach accurately restored experimental conformation of neutral compound 2a 
and predicts in a satisfactory way the electronic transitions (λmax), confirming the robustness of 
the PBE0 functional. 
 
  
N
O
Br
F
OH
O
OHO
                      
 
λ1max = 382 nm 
λ2max = 303 nm 
 
Figure 3.2. (Left) Most stable conformation and electronic transitions calculated for neutral compound 2a. (Right) 
Experimental UV/Vis spectra recorded in a methanol/water mixture (80:20) under three typical pH, corresponding 
to the neutral (1,4), mono-anionic (6.2) and di-anionic (10.0) forms. 
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Figure 3.3. Frontier orbitals for neutral compound 2a (contour threshold: 0.4 au). 
 
Two stable conformations with a low energy difference (+ 0.44 kcal/mol) and a C2-C3-C18-
C19 torsion angle of -57° and 180° were identified for di-anionic compound 2a (Figure 3.4). For 
both species, the DKA side chain was almost planar though the terminal carboxylate group 
undergoes a deviation from planarity of 10° or 15°. All C=O bond lengths of DKA were equal 
to 1.250 ± 0.006 Å indicating that the negative charges were delocalized on the side chain. This 
was confirmed by the partial atomic charge analysis that allowed to calculate a charge of -1.70 
e  (T1 = -52°) and -1.75 e  (T1 = 180°) for the DKA moiety. The UV-visible spectra of 
dianionic species were obtained in aqueous solution (H2O/MeOH (80/20)) at pH value higher 
than 7 (Figure 3.2 right). This spectrum showed a strong absorption at 330 nm. The simulated 
spectra with the 6-311+G(2d,p) basis set for the two most stable conformations were in 
agreement with experimental spectra, with one strong absorption band at 327 nm (T1 = -52°) 
and 353 nm (T1 = 180°) mainly due to π-π* transitions corresponding to an electron transfer 
from the side chain to the quinolone moiety. The very weak difference of 3 nm observed 
between the electronic transition calculated for the stable conformation with T1 = -52° and the 
experimental value is probably partially originating in a error compensation (functional/solute-
solvent hydrogen bonds), as it is known that the description of a di-anionic organic compounds 
remains difficult with TD-DFT.
158
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Figure 3.4. Most stable conformation and corresponding electronic transitions calculated for di-anionic compound 
2a. 
 
 3.1.3. Magnesium-chelating properties of DKA moiety 
 
Due to the low available amount of quinolonyl DKA compounds and their poor solubility 
in aqueous solution, we decided to study the magnesium-chelating properties of DKA moiety in 
solution state using an aryl diketoacid (ADKA) model compound commercially available 
(Figure 3.5).  
 
O OH
OH
O
 
 
Figure 3.5. Structure of aryl diketoacid (ADKA) model compound. 
 
IR spectra of di-anionic ADKA in Tris-buffered aqueous solution (pH > 7.4) containing 
MgCl2.6H2O was recorded using attenuated total reflectance (ATR) spectroscopy (Figure 3.6). 
In this technique, the liquid sample is put on a crystal (ZnSe) of high refractive index. A beam 
of infrared light is passed through this one, resulting in multiple internal reflections which 
extend into the sample. Diketoacid functional groups directly involved in the interaction with 
Mg
2+
 ions were identified by observing the shift of carbonyl stretching vibrations. The IR 
spectrum for di-anionic ADKA (Figure 3.6a, left) showed four characteristics bands 
corresponding to the carbonyl groups of diketoacid moiety. The bands at 1590 and 1508 cm
-1
 
were assigned to the symmetric and asymmetric carbonyl stretching vibration of ketoenolate 
group whereas the bands at 1555 and 1375 cm
-1
 were assigned to the symmetric and 
asymmetric stretch of carboxylate moiety.  
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Upon the addition of MgCl2.6H2O to the di-anionic ADKA solution, all carbonyl stretching 
vibrations were shifted towards higher frequency (Figure 3.6b, left), indicating that both keto-
enolate and carboxylate group of DKA side chain interacted with Mg
2+
 ions. Bathochromic 
shifts of the π-π* transition that we observed by UV-visible analysis of ADKA and compound 
2a following the addition of increasing concentrations of magnesium ions in aqueous solutions 
(Figure 3.6 right) implied that complexation by Mg
2+
 increased the electronic density along 
DKA moiety. Although these data do not allow to obtain a quantitative determination of the 
complexation constant as well as the stoechiometry of the complex formed, it give a good 
indication of the interaction between DKA side chain and Mg
2+
 ions. 
 
  
 
 
 
 
 
 
 
Figure 3.6. (Left) ATR spectra of a) 0.2 M di-anionic ADKA in aqueous buffer (Tris-HCl, pH 10.0) and b) in the 
presence of 0.4 M magnesium. (Right) UV-visible spectra of 5 x 10
-5
 M di-anionic ADKA in aqueous buffer (Tris-
HCl, pH 10.0) (Top) and compound 2a in MeOH/water buffer (Tris-HCl, pH 10.0) (Bottom) alone (black line) and 
in the presence of increasing concentrations of magnesium (color lines). The arrows indicate the batochromic shift 
upon addition of magnesium. 
 
Based on these results, it was plausible to propose a two-metal chelating mode of DKA 
moiety in solution where both the magnesium binding sites are involved in the sequestration of 
metal ions. This coordination mode is in agreement with mass data and potentiometric 
measurement which suggested two magnesium ions octahedrally coordinated by the diketoacid 
moiety and other ligands (water molecules, another diketoacid chain, ...) (Figure 3.7).
143,159
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Figure 3.7. Structural hypothesis for the chelation mode of diketoacid moiety with Mg
2+
 ions. Ligands (water 
molecules, diketoacid moiety, ...) completing the octahedral geometry of magnesium ions are denoted as L. 
 
3.2. Molecular modeling study 
 3.2.1. HIV-1 IN/DNA model building 
 
Due to the lack of HIV-1 IN/DNA experimental structures, the building of a reliable model 
is essential for predicting docking of INSTIs. The polynucleotidyl transferase family comprises 
numerous DNA-binding enzymes involved in a wide range of processes such as transposition, 
viral DNA integration, replication and repair of DNA, homologous recombination and RNA-
mediated gene silencing. Among these, Tn5 transposase and PFV IN showed remarkable 
mechanistic similarities with HIV-1 IN by catalyzing the same two-step metal-dependent 
process. While these two enzymes have low overall primary sequence identity with HIV-1 IN 
(~ 7 % for Tn5 transposase and ~ 20 % for PFV IN), structure-based sequence alignment 
(Discovery Studio software
160
) of the catalytic core domains (Figure 3.8) revealed a common 
RNaseH-like fold with highly conserved active site residues such as the DDE triad and lysine 
residues involved in Mg
2+
 sequestration and DNA binding, respectively. Moreover, the active-
site loop of PFV IN (residues 211-220) directly involved in separating the viral DNA strands 
shares high sequence identity with the one of HIV-1 IN (residues 140-149). Based on these 
considerations, the available crystal structures of Tn5 transposase/DNA transposon and PFV 
IN/DNA complexes provided useful scaffold for modeling the engagement of DNA with the 
active site of HIV-1 IN.  
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Figure 3.8. Structure-based alignment of Tn5 transposase and PFV IN with HIV-1 IN. The alignment was based 
on RnaseH fold of catalytic core domains and RMSD (3.224 Å and 2.178 Å for PFV IN and Tn5 transposase, 
respectively) calculated using Cα atoms. Secondary structure of proteins are shown as cartoon and color-coded: 
grey for HIV-1 IN, magenta for PFV IN and cyan for Tn5 transposase. Identical amino acid residues conserved 
across all three proteins are marked in black, while similar residues are marked in grey. DDE motifs which bind 
metal cations and residues interacting with DNA are marked by ▲ and ●, respectively. 
 
Based on the recent crystal structure of PFV IN in complex with its cognate DNA and 
INSTIs, models of HIV-1 IN/DNA complex in its active and INSTI inhibited forms have been 
reported
161,162
.  
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Nevertheless, these simulated structures did not consider the octahedral inner sphere 
coordination environments of the two active-site Mg
2+
 ions, in particular explicit water 
molecules which could be involved in the catalytic reaction mechanism. Interestingly, by 
superimposing the Cα atoms of the DDE active site residues of Tn5 transposase (PDB code 
1MUS)
163
, PFV IN (PDB code 3L2S)
112
 and HIV-1 IN CCD (PDB code 1BL3C)
106
, water 
molecules present in both Tn5 transposase and HIV-1 IN crystal structures occupy similar 
positions and complete the octahedral geometry of the two divalent metal ions from PFV 
crystal structure (Figure 3.9). The 5’ phosphate group of Tn5 transposon superimposes with 
both bridging (w4) and apical (w1) water molecules from HIV-1 IN CCD. This superimposition 
reveals a plausible conformation of a scissile phosphodiester group from the target DNA 
interacting with the two divalent ions by displacing two water molecules. In this way, the 
scissile phosphodiester group might be properly positioned for the attack of the 3’-OH 
nucleophilic group of the viral DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Superimposition of the active sites of HIV-1 IN, Tn5 transposase and PFV IN based on the positions 
of C-α atoms of the active-site DDE residues. Side chains of DDE-motif and terminal nucleotides are shown as 
sticks. Divalent metal ions (labeled A and B) and waters molecules (labeled w) are shown as spheres. The arrow 
indicates the 3’-OH end attacking the scissile phosphate of the target DNA mimicked by the 5’-phosphate end of 
Tn5 transposon. 
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These observations prompted us to build a model of the HIV-1 IN/DNA complex in its 
INSTI inhibited form by considering explicit water molecules (see material and methods for 
procedure details).
153
 HIV-1 IN/DNA model building was initiated by overlaying the structures 
of HIV-1 IN CCD (1BL3C)
106
, Tn5 transposome (1MUS)
163
 and elvitegravir-bound PFV 
structure (3L2U)
112
 with their Cα positions of active-site DDE residues. This step properly 
oriented PFV DNA substrate, metal ions and explicit water molecules within the active site of 
HIV-1 IN (Figure 3.10). This superimposition was followed by (a) the mutation of PFV DNA , 
(b) the modeling of two Mg
2+
 ions and the merging of water molecules, c) the reorientation of 
glutamate residues to interact with Mg
2+
 ion and (d) the construction of the active-site loop to 
obtain after minimization procedure a new model used as template to perform docking studies.  
 
 
 
Figure 3.10. Schematic representation of the different steps followed in the building of HIV-1 IN/DNA model. 
The two Mg
2+
 ions and coordinated water molecules (w) are shown as green and red spheres, respectively. The 
nontransferred (orange) and reactive (magenta) DNA strand are shown as cartoon. Catalytic core domain is shown 
as grey cartoon. 
 
 3.2.2. Docking studies 
 3.2.2.1. Validation of docking method 
 
Before studying the interaction between quinolone compounds and the modeled HIV-1 
IN/DNA complex, docking software (Gold
164
) was validated to check if it allowed to correctly 
position a ligand in a target enzyme as observed in the crystal structure.  
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Because no experimental structure of HIV-1 IN in complex with DNA substrate and INSTI was 
reported, we simulated the interaction between PFV IN/DNA complex and INSTIs (raltegravir 
and elvitegravir) which crystal structures of ternary complexes are available in the Protein Data 
Bank. Docking results (figure 3.11) indicated that Gold procedure faithfully predicted the 
binding mode observed in crystallographic structures, with RMSD deviation between the 
predicted and observed atom positions of 0.98 and 2.03 Å for raltegravir and elvitegravir, 
respectively. This procedure was so used to predict the binding mode of quinolone compounds 
in the active site of modeled enzyme. 
                  
          
 
Figure 3.11. Comparaison between poses of raltegravir (left) and elvitegravir (right) within the active site of PFV 
IN/DNA complex obtained by docking (yellow) and crystallography (cyan). 
 
 3.2.2.2. Docking of quinolonyl DKA compounds within HIV-1 IN/DNA model 
 
 Docking of the best DKA quinolone compounds (2a, 2b and 2c) in the newly built model 
was performed with the Gold Software.
164
 All these compounds showed a similar interfacial 
binding mode in which the DKA moiety chelated the two Mg
2+
 ions (see docking result of 2a, 
Figure 3.12). In this orientation, the w1 (bridging) and w4 (apical) coordinated water molecules 
were totally displaced by carboxylate and enolate oxygen atoms, respectively, whereas the keto 
oxygen atom replaces the 3’-OH extremity of viral DNA. As a result, the displaced 3’-
adenosine terminal base (A17) was involved in a π-stacking interaction with the quinolone ring 
in such a way that bromine atom at C-6 pointed out to the solvent-exposed surface. The p-F-
benzyl group fitted within a tight pocket formed by cytosine 16 (C16), guanine 4 (G4) and two 
catalytic loop residues P145 and Q146. The fluorobenzyl group made π-stacking interaction 
with C16 taking the space originally occupied by A17. These docking results are in agreement 
with the SARs observed.  
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Indeed, the chelation of the carboxylate group to Mg
2+
 ion could explain the stronger inhibitory 
potency of acidic compounds compared to ester compounds. Moreover, the orientation of the 
substituent at position 6 of the quinolone scaffold towards the solvent-exposed surface could 
also explain the unmodified potency of 6-substituted quinolone derivatives. The observed 
binding mode for DKA quinolone compounds suggests resistance profiles similar to raltegravir 
and elvitegravir. Both Q148H/R/K and N155H resistance pathways, implying a energetic 
penalty upon the binding of the inhibitor and the moving of the two magnesium ions which 
destabilises the complexation of the chelating moiety, are very susceptible to reduce inhibitory 
potency of DKA quinolone compounds. Due to the absence of interactions between quinolone 
compounds and Y143, the resistance pathway involving the mutation Y143R/C should not 
reduce the susceptibility of the inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Docking result of compound 2a (yellow) into the HIV-1 IN/DNA model. The two Mg
2+
 ions and 
coordinated water molecules (w) are shown as green and red spheres, respectively. The nontransferred (orange) 
and reactive (magenta) DNA strands are shown as cartoon. Catalytic core domain is shown as grey cartoon with 
main amino acids as sticks. Note that the two Mg
2+
 ions are octahedrally coordinated by the DDE motif, water 
molecules and the diketoacid chain of the quinolone inhibitor. 
 
These molecular modeling studies allow us to propose a mechanism of inhibition by DKA 
compounds (Figure 3.13).
153
 After the processing of viral DNA, the active site of HIV-1 IN 
adopts an active conformation in which two Mg
2+
 ions are octahedrally coordinated by the 
DDE motif, the 3’-OH extremity and water molecules.  
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This active conformation facilitates the binding of a scissile phosphodiester group from target 
DNA which displaces bridging (w1) and apical (w4) water molecules from the active site, 
forming the ST complex. Once the inhibitor binds in the active site, the chelating moiety (DKA 
chain) interacts with the two Mg
2+
 ions by displacing the 3’-OH extremity and the two water 
molecules originally occupied by the phosphodiester group. The newly formed octahedral 
complex is then stabilized by the properly oriented hydrophobic benzyl moiety by replacing the 
3’ A17 displaced from the active site to form a tighter complex. In this way, the inhibitor 
prevents the formation of the ST complex rendering it catalytically inactive. This mechanism of 
action is in agreement with the two-step mechanism of binding of INSTIs proposed by Garvey 
et al..
165
 
 
                                                                      
 
 
Figure 3.13. Mechanism of inhibition for quinolonyl DKA compounds.  
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3.3. Conclusion 
 
 In this third chapter of results, physicochemical and molecular modeling studies were 
investigated to elucidate the binding mode of quinolone compounds to HIV-1 IN/DNA 
complex. X-ray diffraction, UV-visible spectroscopy and theoretical calculations allowed to 
identify two most stable conformations of the diketoacid moiety. Spectroscopic 
characterization (ATR, UV-vis) of DKA derivative/Mg
2+
 complexes allowed to postulate a 
two-metal chelating mode by the DKA moiety. Docking studies performed on a newly build 
HIV-1 IN DNA model allowed to propose a mechanism of inhibition for quinolonyl DKA 
compounds in agreement with the biological activities we observed and biochemical study of 
HIV-1 IN inhibition kinetic.   
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HIV-1 is the causal agent of AIDS. In the design of new antiviral agents, HIV-1 IN 
constitutes an attractive target because this enzyme plays a major role in the viral replication 
cycle by catalyzing the integration of viral DNA into the host cell DNA. 
 
The objective of this work was to study the inhibition mechanism of HIV-1 IN by 
quinolone compounds with the aim to provide a detailed understanding of the mechanism 
of action of INSTIs. 
 
In a first time, we explored the effect of chemical modifications at position 6 of the 
quinolone scaffold by synthesizing new compounds containing at C-6 bromine atom, acrylate 
or p-fluoro-benzyloxy groups and evaluating their antiviral and anti-integrase activities. The 
expression and purification of active wild-type HIV-1 IN allowed to evaluate IC50 values of the 
synthesized quinolone compounds. The results of in vitro assays showed that acid derivatives 
were more potent than their corresponding esters, with in each case a selectivity for the ST 
reaction. The introduction of both hydrophilic and hydrophobic substituents at C-6 did not 
modified potency against HIV-1 IN. Antiviral data, which were in agreement with enzymatic 
activity, showed that quinolone compounds inhibited viral replication in cells at non-cytotoxic 
concentrations. 
 
Having in mind to crystallize enzyme-ligands complexes, HIV-1 IN CCD was expressed 
and purified. All purification attempts performed did not allow to obtain a sufficient amount of 
pure enzyme to perform cristallization. Giving the fact that HIV-1 IN CCD was previously 
crystallized without His6-tag
106
, thrombin cleavage of purified His-tagged enzyme collected 
after affinity chromatography should be performed. Thrombin as well as non-cleaved fraction 
of protein would be then separated from the cleaved protein by passing successively sample 
through benzamidine sepharose and Ni-NTA column. The cleaved HIV-1 IN CCD isolated 
could be finally purified using other purification techniques. 
 
To predict the binding mode of quinolone compounds within the active site of HIV-1 IN, 
physicochemical studies were performed to identify stable conformations as input for docking 
studies. X-ray diffraction structure determination of compound 2a revealed that the diketo acid 
chain was present under keto enol form and coplanar with the quinolone ring (Figure 1 left). 
Complementary theoretical calculations on the di-anionic form of compound 2a considering 
solvent effects indicated the existence of two stable conformations in solution (∆E = 0.44 
kcal/mole), with one of these corresponding to the experimental structure obtained by XRD 
(Figure 1 right).  
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A solution-state study of the complexation of diketoacid model compound with Mg
2+
 ions 
using ATR and UV-visible spectroscopy allowed to propose a two-metal chelating mode by the 
DKA moiety where both magnesium binding sites of the chelating moiety are involved in the 
sequestration of metal ions. 
                    
                                                                                     
 
 
 
 
 
 
 
Figure 1. (Left) Crystal structure of compound 2a with displacement ellipsoids at the 30% probability level. 
(Right) Stable conformation of di-anionic compound 2a obtained using DFT calculations at PCM-PBE0/6-
311G(d,p) level. 
 
Based on these physicochemical studies, 
we have modeled the interaction between 
quinolone compounds and the DNA-bound 
form of HIV-1 IN. A structural analysis of the 
catalytic core domain of HIV-1 IN, Tn5 
transposase and PFV IN led us to build a new 
HIV-1 IN/DNA model taking into account 
explicit water molecules to complete the 
octahedral geometry of the two active-site 
magnesium ions.  
 
Our further docking studies including water molecules predicted an interfacial binding 
mode in agreement with the biological activities we observed in which the DKA moiety 
chelated the two Mg
2+
 ions by displacing two water molecules from the active site and replaced 
the 3’-OH extremity of viral DNA (Figure 2). The quinolone ring and p-F-benzyl group were 
involved in π-stacking interactions with terminal nucleotides in such a way that substituent at 
C-6 pointed out to the solvent-exposed surface.  
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Finally, molecular modeling studies led us to propose a mechanism of inhibition for 
quinolonyl DKA compounds highlighting a two-step binding reaction (Figure 3). In this 
mechanism, the inhibitor firstly form an octahedral complex by displacing 3’-OH extremity and 
water molecules originally occupied by the host DNA phosphodiester group. This complex is 
then tightened due to the replacement of the displaced 3’ A17 by the hydrophobic benzyl 
moiety. 
 
                                                                                           
 
 
 
Figure 3. Mechanism of inhibition for quinolonyl DKA compounds.  
 
This work provides new structural insights into the mechanism of action of INSTIs and 
opens interesting perspectives for rational design of new inhibitors.  
 
Pharmacomodulations around the quinolone scaffold could be notably investigated to 
increase inhibitory potency and biodisponibility of the quinolonyl DKA derivatives (Figure 4). 
Benzyl group at N-1 involved in π-stacking interaction with DNA substrate could be 
substituted at various positions by halogen atoms (F, Cl) or replaced by DNA base analogs to 
obtain quinolone derivatives having higher affinity for the DNA-bound form of HIV-1 IN. 
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Quinolonyl DKA  
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Giving the fact that substituents at C-6 of the quinolone scaffold do not interact with HIV-1 
IN/DNA complex, hydrophilic aminoalkyl or hydroxyl groups could be introduced at C-6 to 
improve solubility of the compounds. The chemically unstable diketoacid moiety known to 
bind irreversibly plasma proteins could be replaced by a more stable chelating moiety. The 
replacement by a 4-oxo-3-hydroxyfuran-2(5H)-one moiety could improve pharmacokinetic profile as 
well as enforce coplanarity of the heteroatoms. 
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Figure 4. Propositon of pharmacomodulations at 1-, 3- and 6-position of the quinolone scaffold to increase 
inhibitory potency and biodisponibility of quinolonyl DKA compounds. 
 
The newly build HIV-1 IN/DNA model could be used as a platform to develop new compounds 
with improved affinity and selectivity. In silico screening of large compounds libraries could be first 
performed to identify new promising structures. Another computational approach should be 
fragment-based de novo design in which a library of fragments are screened, positioned into the 
enzyme active site and finally linked together to generate a variety of new molecules. In parallel, 
the high-throughput colorimetric assay could be optimized to screen potential inhibitors 
identified. 
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Beside quinolonyl DKA compounds, we disposed of another series of quinolone 
compounds presenting at C-3 carboxylic moiety. The possibility to substitute at various 
positions around the quinolone scaffold makes it a privileged structure for obtaining new 
compounds able to act on another step of the viral replication cycle.  
 
A possible line of research to envisage should be the inhibition of LEDGF/p75-IN 
interaction.
149-151
 This new therapeutic approach could be interesting to overcome the 
appearance of viral strains resistant to current HIV-1 IN inhibitors. The recent crystal structure 
of 2-(quinolin-3-yl)acetic acid compound in complex with the LEDGF/p75-binding pocket 
located within HIV-1 IN CCD highlights the possibility to prevent the binding of host cell 
cofactor LEDGF/p75 to HIV-1 IN essential for host cell DNA targeting of HIV-1 IN 
during integration process.
149
 In this complex (Figure 5 left), the inhibitor mimics the Ile365 
and Asp366 dipeptide located in the LEDGF/p75 integrase binding domain loop by forming 
equivalent hydrogen bonds between carboxylate moiety and the main chain nitrogens of 
residues Glu170 and His171 and occupying the hydrophobic region formed by Leu102, Ala128 
and Ala129. Interestingly, docking of unsubstituted quinolone compounds within the 
LEDGF/p75 binding pocket of HIV-1 IN CCD (Figure 5 right)  showed that quinolone rings 
occupy the hydrophobic region pocket whereas diketoacid chain and carboxylate moiety form 
hydrogen bonds with E170 and H171 residues involved in the recognition process between IN 
and LEDGF/p75. These results suggest that these scaffolds could constitute a starting point 
toward the design of new inhibitors of LEDGF/p75-IN interaction. The crystallization of 
enzyme-ligand complexes would be useful in the optimization of lead compounds. For that 
purpose, further optimization of the purification of the HIV-1 IN CCD produced during our 
work could be investigated.  
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Figure 5. (Left) Cartoon representation of the integrase core dimer (grey) with the soaked 2-(quinolin-3-yl)acetic 
acid compound
149
 (cyan stick) superimposed with the LEDGF/p75-IN complex structure (PDB code 2B4J)
114 
revealing mimicry of the protein-protein interaction by the inhibitor. LEDGF/p75 protein is shown as green 
cartoon. (Right) Docking results of unsubstituted quinolonyl diketoacid (yellow stick) and 3-carboxylic acid 
quinolone (light blue stick) compound within the LEDGF/p75 binding pocket of the IN-core (PDB code 2B4J).
114
 
 
Another interesting strategy would be the design of dual inhibitors of HIV-1 IN and RT 
enzyme.
166-168
 This novel and attractive therapeutic way could alleviate the major issues 
occurring during combination therapy such as toxicity and quick emergence of drug resistance. 
RT enzyme catalyzes reverse transcription of viral RNA into viral DNA using RNA/DNA 
dependent polymerase and Rnase H activities. RT RnaseH domain and HIV-1 IN CCD share 
similar fold structures with the same DDE triad sequestering divalent metal ions absolutely 
required for catalytic activity. In this context, the simultaneous inhibition of HIV-1 IN and RT 
RnaseH activities by metal-chelating compounds appear an interesting approach to design dual 
inhibitors. Because quinolonyl DKA and 3-carboxylic quinolone compounds possess chelating 
moiety able to bind two divalent metal ions, these one could be considered as potential lead for 
the development of novel dual IN/RNaseH inhibitors. 
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1   Chemistry 
 
All the reagents and solvents employed were used without further purification. 
1
H NMR 
and and 
13
C NMR spectra were recorded on a Jeol JNM EX-400 spectrometer. Chemical shifts 
(δ scale) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) used 
as an internal standard. Infrared (IR) spectra were recorded to the solid state on a Perkin-Elmer 
Spectrum 65. Melting points were determined with a TOTOLLI-BUCHI Melting Point B-545 
apparatus. Analytical thin-layer chromatography (TLC) was done on Merck silica gel 60 F254 
plates. Mass spectra were recorded on an 1100 series MSD Trap spectrometer equipped with an 
electron spray ionization (ESI) source. 
 
Synthesis of 2-aminomethylene intermediates (3a,b). (i) General method. An equimolar 
mixture of ethylethoxymethyleneacetoacetate (4.6 g, 23 mmol) and appropriate substituted aniline (23 
mmole) was stirred at 120°C for 10 min. After cooling, the formed precipitate was filtered and 
washed with n-hexane to obtain pure compound 3a,b used in the next reaction without further 
purification. 
(ii) 2-[[(4-bromophenyl)amino]methylene]-3-oxobutanoic acid ethyl ester (3a): White solid, 
yield: 62 %, mp: 102°C. 
1
H NMR (CDCl3, 400 MHz): δ 1.34 (t, 3H, CH2CH3), 1.41 (t, 3H, 
CH2CH3), 2.47 (s, 3H, CH3), 2.54 (s, 3H, CH3), 4.26 (q, 2H, CH2CH3), 4.31 (q, 2H, CH2CH3), 
7.05 (d, 2H, J = 8.8 Hz, benzene H), 7.49 (d, 2H, J = 8.8 Hz, benzene H), 8.43 (d, 1H, J = 13.7 
Hz, C=CH), 12.71 (d, 1H, J = 13.5 Hz, NH).  
(iii) 2-[[(4-phenol)amino]methylene]-3-oxobutanoic acid ethyl ester (3b): Yellow solid, 
yield: 55 %, mp: 113°C. 
1
H NMR (DMSO-d6, 400 MHz): δ 1.22 (t, 3H, CH2CH3), 2.36 (s, 3H, 
CH3), 2.54 (s, 3H, CH3), 4.10 (q, 2H, CH2CH3), 6.76 (d, 2H, J= 8.8 Hz, benzene H), 7.18 (d, 
2H, J = 8.8 Hz, benzene H), 8.29 (d, 1H, J= 13.7 Hz, C=CH), 9.54 (s, 1H, OH), 12.54 (d, 1H, J 
= 13.7 Hz, NH). 
  
Synthesis of 3-Acetyl-4(1H)-quinolinones intermediates (4a,b). (i) General method. 4.2 g 
of appropriate intermediates 3a,b (17 mmol) was added portionwise to 200 ml of boiling 
diphenyl ether previously heated at 250°C. The solution was kept at 250°C for 1h30. After 
cooling, the formed precipitate was collected. The crude product was purified by 
chromatography on silica gel column (EtOH/CH2Cl2 as eluant) to provide pure derivative 4a,b. 
(ii) 3-acetyl-6-bromo-4(1H)-quinolinone (4a): Brown solid, yield: 74 %, mp: > 250°C. 
1
H 
NMR (DMSO-d6, 400 MHz): δ 2.58 (s, 1H, CH3), 7.57 (d, 1H, J8,7 = 8.7 Hz, C8-H 
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quinolinone), 7.84 (dd, 1H, J7,5 = 2.6 Hz, J7,8 = 8.7 Hz, C7-H quinolinone), 8.26 (d, 1H, J5,7 = 
2.6 Hz, C5-H quinolinone), 8.52 (s, 1H, C2-H quinolinone). 
(iii) 3-acetyl-6-hydroxy-4(1H)-quinolinone (4b): Brown solid, yield: 46 %, mp: > 250°C. 
1
H 
NMR (DMSO-d6, 400 MHz): δ 2.56 (s, 1H, CH3), 7.15 (dd, 1H, J7,5 = 2.6 Hz, J7,8 = 8.7 Hz, C7-
H quinolinone), 7.46 (d, 1H, J8,7 = 8.7 Hz, C8-H quinolinone), 7.51 (d, 1H, J5,7 = 2.6 Hz, C5-H 
quinolinone), 8.37 (s, 1H, C2-H quinolinone), 9.91 (bs, 1H, OH). 
 
Synthesis of 3-Acetyl-1-(4-fluorophenyl)methyl-4(1H)-quinolinones (5a,b). (i) General 
method. 4-Fluorophenylmethyl bromide (1.7 g, 9 mmol) and anhydrous K2CO3 (1.3 g, 9 mmol) 
was added to a mixture of appropriate intermediates 4a,b in dry DMF (30 ml). The resulting 
suspension was stirred at 100°C for 5 h. After the mixture was cooled, water (50 ml) was added 
and the precipitate was filtered, washed with petroleum ether and purified by chromatography 
on silica gel column (AcOEt/petroleum ether 4/6 and then AcOEt as eluant). 
(ii) 3-acetyl-1-((4-fluorophenyl)methyl)-6-bromo-4(1H) quinolinone (5a): Brown solid, yield: 85 
%, mp: 203°C.
 1
H NMR (CDCl3, 400 MHz): δ 2.80 (s, 3H, CH3), 5.36 (s, 2H, CH2), 7.05-7.12 
(m, 4H, Ar-H), 7.2 (d, 1H, J8,7 = 9.4 Hz, C8-H quinolinone), 7.64 (dd, 1H, J7,5 = 3 Hz, J7,8 = 9.4 
Hz, C7-H quinolinone), 8.61 (s, 1H, C2-H quinolinone), 8.65 (d, 1H, J5,7= 3 Hz, C5-H 
quinolinone). 
(iii) 3-acetyl-1-((4-fluorophenyl)methyl)-6-(4-fluorobenzyloxy)-4(1H) quinolinone (5b): Yellow 
solid, yield: 73 %, mp: 219°C.
 1
H NMR (DMSO-d6, 400 MHz): δ 2.61 (s, 3H, CH3), 5.16 (s, 
2H, CH2), 5.62 (s, 2H, CH2), 7.1-7.3 (m, 6H, Ar-H), 7.35 (dd, 1H, J7,5 = 3 Hz, J7,8 = 9.4 Hz, C7-
H quinolinone), 7.44-7.52 (m, 2H, Ar-H), 7.61 (d, 1H, J8,7 = 9.4 Hz, C8-H quinolinone), 8.65 
(d, 1H, J5,7= 3 Hz, C5-H quinolinone), 8.78 (s, 1H, C2-H quinolinone). 
 
Synthesis of (E)-ethyl [3-acetyl-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-6-yl] acrylate 
(5c): 3-acetyl-6-bromo-1-((4-fluorophenyl)methyl)-4(1H)-quinolinone (5a) (0.450 g, 1.2 mmol) 
was added to a mixture of acrylic acid ethyl ester (0.202 g, 2.4 mmol), Pd(OAc)2 (0.013 g, 
0.06mmol), PPh3 (0.061 g, 0.24 mmol) and NEt3 (0.134 g, 1.2 mmol) in 3 ml of DMF. The 
reaction mixture was stirred under argon for 48 h at 80°C. The reaction was cooled to room 
temperature and extracted with ethyl acetate. The organic phases were washed four times with 
brine (10 ml) and dried with MgSO4. Upon removal of the solvent, the residue obtained was 
purified by chromatography on silica gel column (ACOEt/petroleum ether 3/7 and then 1/1 as 
eluant) to afford pure derivative 5c. Yellow solid, yield: 62 %, mp: 220°C. 
1
H NMR (CDCl3, 
400 MHz): δ 1.33 (t, 3H, CH2CH3), 2.82 (s, 3H, CH3), 4.26 (q, 2H, CH3CH2), 5.38 (s, 2H, 
CH2), 6.51 (d, 1H, Jtrans= 16 Hz, CH=CH), 7.02-7.18 (m, 4H, Ar-H), 7.32 (d, 1H, J8,7 = 8.9 Hz, 
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C8-H quinolinone), 7.71 (dd, 1H, J7,5= 1 Hz, J7,8= 8.9 Hz, C7-H quinolinone), 7.73 (d, 1H, Jtrans= 
16 Hz, CH=CH), 8.59 (s, 1H, C2-H quinolinone), 8.65 (d, 1H, J5,7= 1 Hz, C5-H quinolinone). 
Synthesis of diketo esters derivatives (1a-c). (i) General method. Freshly prepared sodium 
ethoxide (0.272 g, 2 mmol) was added to a well stirred mixture of diethyl oxalate (0.584 g, 4 
mmol) and appropriate acetyl derivative 5a-c (2 mmol) in anhydrous THF (2 ml) under 
nitrogen atmosphere. The reaction mixture was stirred at room temperature for 20h. n-hexane 
(70 ml) was added and the formed precipitate was filtered, washed with n-hexane and stirred 
for 30 min in 1N HCl (70 ml). The solid was filtered off and washed with n-hexane. Residual 
water was removed by azeotropic distillation using acetonitrile to provide pure diketo esters 1a-
c.  
(ii) Ethyl [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl]-4-hydroxy-2-oxo-3-
butenoate (1a): Yellow solid, yield: 83 %, mp: 105°C. IR υmax (KBr/cm
-1
): 1750 (C=O 
carboxylic ester), 1645 (C=O quinolinone), 1594 (C=O + C=C keto-enol). 
1
H NMR (CDCl3, 
400 MHz): δ 1.42 (t, 3H, CH3), 4.40 (q, 2H, CH3CH2), 5.40 (s, 2H, CH2), 7.07-7.18 (m, 4H,Ar-
H), 7.24 (d, 1H, J8,7 = 8.9 HZ, C8-H quinolinone), 7.66 (dd, 1H, J7,5 = 3 Hz, J7,8 = 8.9 Hz, C7-H 
quinolinone), 8.08 (s, 1H, C3-H butenoate), 8.66 (d, 1H, J5,7 = 3 Hz, C5-H quinolinone), 8.72 (s, 
1H, C2-H quinolinone). 
13
C NMR (DMSO-d6, 400 MHz): δ 14.81 (CH3), 56.04 (N-CH2), 62.82 
(CH2), 102.01 (CH), 114.87 (C), 116.24 (d, J = 22.0 Hz, 2C-ArH), 120.06 (CH), 121.6 (CH), 
129.9 (d, J = 8.6 Hz, 2C-ArH), 130.81 (C), 132.04 (C), 136.51 (C), 138.12 (CH), 150.09 (C), 
162.40 (C), 162,51 (d, J = 247.28 Hz, C-ArH), 162.74 (C), 169.58 (C), 174.02 (C), 188.01 (C). 
LC-MS: (M+H)
+
 474.2,  476.0 
(iii) 4-[6-(4-fluorobenzyloxy)-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-
oxo-2-butenoic acid ethyl ester (1b): Yellow solid, yield: 82 %, mp: 160°C. IR υmax (KBr/cm
-1
): 
1743 (C=O carboxylic ester), 1634 (C=O quinolinone), 1605 (C=O + C=C keto-enol). 
1
H NMR 
(DMSO-d6, 400 MHz): δ 1.28 (t, 3H, CH2CH3), 4.27 (q, 2H, CH2CH3), 5.17 (s, 2H, CH2), 5.72 
(s, 2H, CH2), 7.09-7.34 (m, 6H, Ar-H), 7.39 (dd, 1H, J7,5 = 3 Hz, J7,8 = 9.4 Hz, C7-H 
quinolinone), 7.43-7.53 (m, 2H, Ar-H), 7.66 (d, 1H, J8,7 = 9.4 Hz, C8-H quinolinone), 7.79 (d, 
1H, J5,7= 3 Hz, C5-H quinolinone), 8.00 (s, 1H, C3-H butenoate), 9.04 (s, 1H, C2-H 
quinolinone).
 13
C NMR (CDCl3, 400 MHz): 14.26 (CH3), 57.59 (N-CH2), 62.42 (CH2), 69.91 
(O-CH2), 102.47 (CH), 108.58 (CH), 114.27 (C), 115.72 (d, J = 22.0 Hz, 2C-ArH), 116.65 (d, J 
= 22.0 Hz, 2C-ArH), 118.71 (CH), 123.68 (CH), 128.12 (d, J = 8.6 Hz, 2C-ArH), 129.66 (d, J = 
8.6 Hz, 2C-ArH), 130.55 (C), 131.90 (d, J = 2.8 Hz, C-ArH), 133.28 (C), 147.50 (CH), 156.77 
(C), 162.62 (C), 162.73 (d, J = 247.28 Hz, C-ArH), 162.81 (d, J = 248.24 Hz, C-ArH), 169.21 
(C), 174.83 (C), 188.09 (C). LC-MS: (M+H)
+
 520.0. 
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(iv) 4-[6-((E)-3-ethoxy-3-oxoprop-1-enyl)-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic acid ethyl ester (1c): Yellow solid, yield: 79 %, mp: 146°C. IR υmax 
(KBr/cm
-1
): 1733 (C=O carboxylic ester), 1702 (C=O acrylic ester), 1644 (C=O quinolinone), 
1600 (C=O + C=C keto-enol). 
1
H NMR (CDCl3, 400 MHz): δ 1.33 (t, 3H, CH2CH3), 1.41 (t, 
3H, CH2CH3), 4.26 (q, 2H, CH2CH3),  4.40 (q, 2H, CH2CH3),  5.42 (s, 2H, CH2), 6.52 (d, 1H, 
Jtrans= 16 Hz, CH=CH), 7.04-7.20 (m, 4H, Ar-H), 7.36 (d, 1H, J8,7 = 8.7 Hz, C8-H quinolinone), 
7.69-7.76 (m, 2H, CH=CH and C7-H quinolinone), 8.11 (s, 1H, C3-H butenoate), 8.67 (d, 1H, 
J5,7= 2 Hz, C5-H quinolinone), 8.72 (s, 1H, C2-H quinolinone). 
13
C NMR (CDCl3, 400 MHz): 
14.24 (CH3), 14.37 (CH3), 57.46 (N-CH2), 60.87 (CH2), 62.51 (CH2), 102.51 (CH), 115.80 (C), 
116.78 (d, J = 22.0 Hz, 2C-ArH), 117.54 (CH), 120.37 (CH), 127.93 (CH), 128.10 (d, J = 8.6 
Hz, 2C-ArH), 129.29 (C), 129.39 (d, J = 2.8 Hz, C-ArH), 131.86 (C), 132.23 (CH), 139.62 (C), 
142.36 (CH), 148.68 (CH), 162.45 (C), 162.90 (d, J = 249.20 Hz, C-ArH), 166.58 (C), 169.58 
(C), 174.96 (C), 187.55 (C). LC-MS: (M+H)
+
 494.0. 
 
 Synthesis diketo acids derivatives (2a-c). (i) General method. A mixture of the appropriate 
ester 1a-c (1.3 mmol) and 1N NaOH (12 ml) in THF/methanol (1:1, 15 ml) was stirred at room 
temperature for 3h under nitrogen atmosphere, poured onto crushed ice and treated with 1N 
HCl to reach pH 2. The formed precipitate was filtered off and successively washed with water, 
ethanol and petroleum ether to give pure acids 2a-c. 
(ii) [6-bromo-1-(4-fluorophenylméthyl)-4(1H)-quinolinon-3-yl]-4-hydroxy-2-oxo-3-butenoïc 
acid (2a): Yellow solid, yield: 73 %, mp: 192°C. IR υmax (KBr/cm
-1
): 1708 (C=O carboxylic 
acid), 1638 (C=O quinolinone), 1595 (C=O + C=C keto-enol). 
1
H NMR (DMSO-d6, 400 
MHz): δ 5.72 (s, 2H, CH2), 7.15-7.18 (m, 2H, Ar-H), 7.29-7.31 (m, 2H, Ar-H), 7.65 (d, 1H, J8,7 
= 8.9 HZ, C8-H quinolinone), 7.88 (dd, 1H, J7,5 = 3 Hz, J7,8 = 8.9 Hz, C7-H quinolinone), 8.34 
(s, 1H, butenoate C3-H), 8.99 (d, 1H, J5,7 = 3 Hz, C5-H quinolinone), 9.09 (s, 1H, C2-H 
quinolinone). 
13
C NMR (DMSO-d6, 400 MHz): δ 56.02 (N-CH2), 102.04 (CH), 114.77 (C), 
116.34 (d, J = 21.09 Hz, 2C-ArH), 119.26 (CH), 121.23 (CH), 129.28 (C), 129.41 (d, J = 7.67 
Hz, 2C-ArH), 130.31 (C), 132.10 (C), 136.09 (C), 138.28 (CH), 150.09 (C), 162.24 (d, J = 247 
Hz, C-ArH), 164.26 (C), 173.57 (C). LC-MS: (M+H)
+
 446.1, 448.0. 
(iii) 4-[6-(4-fluorobenzyloxy)-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-hydroxy-4-
oxo-2-butenoic acid (2b): Yellow solid, yield: 79 %, mp: 194°C. IR υmax (KBr/cm
-1
): 1731 
(C=O carboxylic acid), 1718 (C=O quinolinone), 1612 (C=O + C=C keto-enol). 
1
H NMR 
(DMSO-d6, 400 MHz): δ 5.17 (s, 2H, CH2), 5.71 (s, 2H, CH2), 7.09-7.34 (m, 6H, Ar-H), 7.39 
(m, 1H, C7-H quinolinone), 7.43-7.53 (m, 2H, Ar-H), 7.68 (d, 1H, J8,7 = 9.4 Hz, C8-H 
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quinolinone), 7.77 (d, 1H, J5,7= 3 Hz, C5-H quinolinone), 7.99 (s, 1H, C3-H butenoate), 9.03 (s, 1H, 
C2-H quinolinone). 
13
C NMR (DMSO-d6, 400 MHz): 56.13 (N-CH2), 69.47 (O-CH2), 102.10 (CH), 
108.93 (CH), 113.35 (C), 115.86 (d, J = 22.0 Hz, 2C-ArH), 116.32 (d, J = 21.0 Hz, 2C-ArH), 120.64 
(CH), 123.11 (CH), 129.39 (d, J = 7.6 Hz, 2C-ArH), 130.31 (C), 130.57 (d, J = 8.6 Hz, 2C-ArH), 
132.35 (C), 133.30 (d, J = 1.9 Hz, C-ArH), 133.56 (C), 148.96 (CH), 156.61 (C), 162.22 
(d, J = 244.41 Hz, C-ArH), 162.36 (d, J = 243.45 Hz, C-ArH), 164.22 (C), 174.33 (C). LC-MS: 
(M+H)
+
 492.0. 
(iv) 4-[6-((E)-3-hydroxy-3-oxoprop-1-enyl)-1-(4-fluorophenyl)methyl-4(1H)-quinolinon-3-yl]-2-
hydroxy-4-oxo-2-butenoic acid (2c): Yellow solid, yield: 70 %, mp: 163°C. IR υmax (KBr/cm
-1
): 
1703 (C=O carboxylic acid), 1698 (C=O acrylic acid), 1636 (C=O quinolinone), 1599 (C=O + 
C=C keto-enol). 
1
H NMR (DMSO-d6, 400 MHz): δ 5.75 (s, 2H, CH2), 6.58 (d, 1H, Jtrans= 16 
Hz, CH=CH), 7.05-7.42 (m, 4H, Ar-H), 7.61-7.78 (m, 2H, CH=CH and C8-H quinolinone), 
7.96 (s, 1H, C3-H butenoate), 8.05 (m, 1H, C7-H quinolinone), 8.43 (d, 1H, J5,7= 2 Hz, C5-H 
quinolinone), 9.08 (s, 1H, C2-H quinolinone).
 13
C NMR (DMSO-d6, 400 MHz): 56.01 (N-CH2), 
102.17 (CH), 116.35 (d, J = 22.0 Hz, 2C-ArH), 119.46 (CH), 121.19 (CH), 127.61 (CH), 
129.41 (d, J = 8.6 Hz, 2C-ArH), 132.06 (C), 132.28 (d, J = 1.9 Hz, C-ArH), 140.07 (C), 142.85 
(CH), 150.01 (C), 150.42 (CH), 162.32 (d, J = 245.37 Hz, C-ArH), 162.85 (C), 164.19 (C), 
167.87 (C), 174.65 (C). LC-MS: (M+H)
+
 438.0. 
 
2   Biology 
2.1. Enzyme production 
 
 Transformation of E. coli
 
BL21(DE3)pLysS chemically competent cells. Plasmids 
encoding recombinant enzymes were introduced into cells in a heat shock step (10 sec at 42°C). 
Then the bacteria were grown up in a small culture (200 µl LB medium for 1 h at 37°c). The 
bacteria were spread on an LB-agar plate containing ampicilline and incubated overnight at 
37°C to allow growing of single bacteria colonies which contained the antibiotic resistance 
gene. Three single colonies were in turn amplified overnight at 37°C in a 5 mL pre-culture (LB 
medium) containing ampicilline (100 µg/ml). 
 
 Expression. (i) General method. Preculture was reseeded and further growned in the 
same LB/ampicilline medium at 37 °C. Once optical density (OD) was reached, fusion protein 
expression was induced in bacterial culture by the addition of 1 mM IPTG. Cultures were  
incubated for 3 h at 37 °C, after which cells were centrifuged at 4°C (30 min at 4000 rpm).
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The cell pellet was resuspended in ice-cold buffer and lysed. After centrifugation at 4°C (40 
min at 10 000 rpm), the supernatant obtained was finally filtered (0.45 µm).  
(ii) His-tagged wild-type HIV-1 IN: IPTG induction was performed at OD 1.0. Cell pellet was 
resuspended in 25 ml buffer A containing 20 mM Tris-HCl (pH 8), 1 M NaCl, 4 mM β-
mercaptoethanol and lysed by French Press (1200 bars).  
(iii) His-tagged HIV-1 IN CCD (F185K): IPTG induction was performed at OD 0.7. Cell 
pellet was resuspended in 10 ml buffer A containing 25 mM HEPES (pH 7.5), 0.5 M NaCl, 2 
mM β-mercaptoethanol, 5 mM Imidazole and lysed by sonication (10 cycles of 30 seconds 
“ON” and 30 seconds “OFF”). 
  
 Western blot. Proteins separated by SDS/PAGE were electrotransferred to Hybond-C 
extra nitrocellulose membrane (Amersham) in PBS buffer (Phosphate Buffered Saline) for 1h 
at constant voltage (80 volts). The membrane was then incubated overnight at 4°C in TBST 
buffer (Tris Buffered Saline, 0.1 % Tween 20) containing 1 % milk (TBSTM). Anti-integrase 
antibodies diluted to 1:1000 in TBSTM were added and incubated for 2 h at room temperature 
under agitation. Anti-rabbit secondary antibodies (horseradish peroxidase conjugated) diluted 
to 1:3000 in TBSTM were added and incubated for 1 h at room temperature under agitation. 
Between each step, the membrane was extensively washed (three times) with TBST. Finally, 
antibodies revelation was performed with ECL plus Western blotting detection system (GE 
Healthcare). 
 
2.2. Enzyme purification 
 
 His-tagged wild-type HIV-1 IN. Ni-NTA agarose beads (Pharmacia) was preequilibrated 
with buffer A and incubated overnight at 4°C with the supernatant of crude E. coli. The beads 
were washed three times with 45 ml of buffer A and 45 ml of buffer A with 80 mM imidazole. 
His-tagged IN was then eluted with buffer A supplemented with 1M imidazole and 50 µM 
ZnSO4 to favour the folding structure of zinc-finger. Finally, a dialysis was performed 
overnight at 4°C against 20 mM TrisHCl (pH 8), 1 M NaCl, 4 mM β-mercaptoethanol, and 
10% (v/v) glycerol. Fractions were aliquoted and rapidly frozen at -80 °C. 
 His-tagged HIV-1 IN CCD (F185 K). (i) Nickel affinity chromatography: Ni-NTA 
sepharose (GE Healthcare) column was preequilibrated with buffer A and loaded with the 
supernatant of crude E. coli at a flow rate of 1 ml/min. Washing buffer A containing 60 mM 
imidazole was applied at a flow rate of 3 ml/min and linear imidazole gradient (from 60 mM to 
1 M) was applied at a flow rate of 1ml/min over a total volume of 100 ml.  
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(ii) Size exclusion chromatography: Protein sample obtained from affinity chromatography 
was dialyzed overnight at 4°C against 25 mM HEPES (pH 7.5), 0.5 M NaCl, 1 mM DTT, 1 
mM EDTA and 10% (v/v) glycerol. Superdex 75 column (GE Healthcare) was preequilibrated with 
elution buffer containing 25 mM HEPES (pH 7.5), 0.5 M NaCl, 1mM DTT and 1 mM
EDTA. 100 µl of protein sample was injected onto the column. Elution buffer was then applied 
at a flow rate of 1 ml/min to elute proteins. 
(iii) Ion exchange chromatography. (A) Anion exchange chromatography: Protein sample 
obtained from affinity chromatography was dialyzed overnight at 4°C against buffer A 
containing 25 mM CHES (pH 9.5), 0.25 M NaCl, 1 mM DTT, 1 mM EDTA and 10 % (v/v) 
glycerol. MonoQ column (GE Healthcare) was preequilibrated with buffer A and loaded with 
protein sample at a flow rate of 0.5 ml/min. Linear gradient of NaCl from 25 mM to 1 M was 
applied at a flow rate of 1 ml/min over a total volume of 100 ml. (B) Cation exchange 
chromatography: Protein sample obtained from affinity chromatography was dialyzed 
overnight at 4°C against buffer A containing 20 mM NaH2PO4 (pH 6), 0.25 M NaCl, 1 M urea, 
1 mM DTT, 1 mM EDTA and 10 % (v/v) glycerol. SP column (GE Healthcare) was 
preequilibrated with buffer A and loaded with protein sample at a flow rate of 0.5 ml/min. 
Linear gradient of NaCl from 25 mM to 1 M was applied at a flow rate of 1 ml/min over a total 
volume of 100 ml.  
 
2.3. His-tag cleavage 
 
Thrombin (50 NIH unit) was added to 1 mg of His-tagged HIV-1 IN CCD and the solution 
incubated for 20, 40 and 60 min at 28°C. Cleaved enzyme was applied at a flow rate of 0.5 
ml/min to a column of Ni-NTA sepharose resin (GE Healthcare) equilibrated with buffer A 
containing 25 mM HEPES (pH 7.5), 0.5 M NaCl, 2 mM β-mercaptoethanol, 5 mM Imidazole. 
Two washing steps were performed with buffer A containing 20 and 60 mM imidazole. Finally, 
a linear imidazole gradient (from 60 to 1M imidazole) was applied at a flow rate of 1 ml/min. 
 
2.4. Biological assays 
 
Radioactive gel-based assays. His-tagged wild-type HIV-1 IN or His-tagged HIV-1 IN 
CCD (F185 K) were incubated with 12.5 nM of the 5’-end 32P-labeled oligonucleotide substrate 
in a reaction buffer (20 mM HEPES pH7.5, 1mM DTT, 10 mM MgCl2, 10% dimethyl 
sulfoxyde) 1 h at 37°C. For His-tagged HIV-1 IN CCD (F185 K), MgCl2 was replaced by 
MnCl2 in reaction buffer. 
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Oligonucleotides were precipitated in a precipitation buffer (3M sodium acetate pH 7, 10 mg/ml 
glycogen, Tris (10 mM)-EDTA (1mM) buffer pH 7.5), extracted with phenol/chloroform and washed 
with ethanol. The oligonucleotides were resuspended in 10 µl of 10 mM formamide/EDTA, 
denatured and separated by electrophoresis on a polyacrylamide/urea gel (16 % acrylamide, 7 M 
urea). Gels were dried, exposed in a PhosphorImager cassette, analyzed using a Storm mode imager 
(Amersham Biosciences) and quantified using ImageQuant. The IC50 values were determined from a 
curve (drug concentration versus percent inhibition) fitted on experimental data (Prism software) to 
obtain the concentration that produced 50 % inhibition.  
 
Colorimetric assay. His-tagged wild-type HIV-1 was incubated with 30 nM biotinylated 
oligonucleotide substrate, 100 nM digoxigenin-labeled oligonucleotide target in a reaction 
buffer (20 mM HEPES pH 6.8, 1 mM DTT, 10 mM MgCl2, 10% dimethyl sulfoxyde) 2 h at 
37°C. The reaction was stopped by adding 60 µl of solution containing 20 mM Tris-HCl, 400 
mM NaCl, 10 mM EDTA and 0.1 mg/ml salmon sperm DNA. The reaction products were 
transferred into 96-well streptavidin-coated plate first incubated for 1 h with PBSTM buffer 
(Phosphate Buffered Saline containing 0.05 % tween 20 and 1 % milk) and washed three times 
with PBST buffer for 5 minutes. The reaction mixture was incubated for 1h at room 
temperature under low agitation and the wells were washed with a washing buffer (30 mM 
NaOH, 200 mM NaCl and 1 mM EDTA) for 5 minutes. 100 µl diluted anti-digoxigenin 
antibodies (1:2000) were added to the wells and incubated at 37°C for 3h30. The wells were 
washed five times with PBST buffer containing 0.1 % HSA (human serum albumin) and 200 µl 
ABTS were added to give green solution quantified using a microplate reader at 405 nm. 
 
Cell-based assays. (i) Cells and viruses: The following reagents were obtained through 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl 
from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. TZM-bl cells were grown at 
37°C, 5% CO2 in DMEM medium (Invitrogen) supplemented with 5% (v/v) heat-inactivated 
bovine serum, 50 U of penicilin/ml and 50 µg of streptomycin/ml (Invitrogen). Exponentially 
growing cells were trypsinised, centrifuged and split twice weekly. The HIV strain used in this 
study is HIV-1 NL4-3 derived from the infectious molecular clone pNL4-3. HIV-1 stocks were 
stored as cell-free supernatants at -80°C.  
(ii) Antiviral activity: Antiviral activity of the compounds was evaluated using the TZM-bl 
cell line.
38
 This TZM-bl cell line uses a Tat protein-induced transactivation of the HIV-1 LTR 
promoter driving the expression of the β-galactosidase gene. In brief, exponentially growing 
cells were plated at 5000 cells/well in flat-bottom 96-well microtiter plates.  
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After a 48 h incubation, the medium was removed and replaced by 100 µl of medium 
containing the quinolinone derivatives at concentrations ranging from 0.00128 to 4 µM. Four 
hours after drug treatment, cells were infected with equal amount of cell-free virus (NL4-3 
strain), corresponding to 100 ng of HIV p24 antigen. Forty-eight hours post-infection, the 
medium was removed and cells were lysed in PBS containing 0.1% NP-40 and 5 mM MgCl2. 
β-galactosidase activity was measured using chlorophenol red β-D-galactopyranoside (Roche) 
assays. The 50% effective concentration (EC50) was calculated from each dose response curve 
using Prism software.  
(iii) Cytotoxicity: Flat bottom 96-well plates were filled with 50 µl of complete medium 
containing 5000 TZM-bl cells. Two hours later, 50 µl of medium containing an appropriate 
dilution of the test compounds (from 100 to 0.032 µM) was added. Cells and compounds were 
incubated at 37°C in growth medium for 3 days. Cell viability was determined by a 
colorimetric assay based on the cleavage of the tetrazolium salt WST-1 (Roche) by 
mitochondrial dehydrogenases in viable cells. Absorbance of converted dye was measured in 
an ELISA plate reader at the wavelength of 570 nm. The cytotoxicity of the compounds was 
calculated as the reduction percentage of viable cells observed in the drug-free control cell 
culture. The drug concentration required to reduce cell viability by 50% was named CC50.  
 
3   Physicochemistry 
3.1. X-ray crystallography 
 
 Crystals of compound 2 were obtained by slow evaporation of an acetone/DMSO solution 
at 4°C. X-ray intensities were collected on a graphite-monochromated CAD-4 Enraf-Nonius 
diffractometer with Cu Kα radiation (λ = 1.54178Å) using θ-2θ scan technique. The structure 
was solved using PLATON.
155
 Non-hydrogen atoms were refined anisotropically while 
hydrogen atoms were calculated geometrically (except H25 and H22 found by Fourier 
difference and fixed at this position). The discrepancy index R is equal to 6,6%. Structure 
coordinates have been deposited in the Cambridge structural database (CCDC730039). 
 
     
 
 
 
       Formula                                                   C22 H19 BR F N O6 S   
        Formula Weight                                                            524.35   
        Crystal System                                                                                                    Monoclinic   
        Space group                                                                                            P21/c        (No. 14)   
        a, b, c [Angstrom]                                                              5.105(3)     26.98(1)    16.093(5)   
        alpha, beta, gamma                                                                               90    97.705(8)     90   
        V [Ang**3]                                                                                                          2196.5(17)   
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3.2. Solution-state study 
 
Experiment. (i) UV-visible absorption: UV-visible spectra were recorded on an 
UVIKON 930 UV spectrophotometer at room temperature. All measurements were carried out 
with a final concentration of compounds of 5 x 10
-5
 M. Compound 2 was solubilized in 
methanol/water mixture (80:20) and ADKA in water solution.  The pH was adjusted by adding 
non-absorbing buffer solutions to a final concentration of 0.1 M. Citrate and tris(hydroxy-
methyl)amino methane (Tris) buffers were used at pH 1.4 and 10.0, respectively. An aqueous 
solution of magnesium chloride hexahydrate (MgCl2.6H2O) at 1x10
-4
 M was prepared and 
added to compounds in equal volume. 
(ii) Attenuated total reflectance: ATR spectra were recored on a Perkin-Elmer Spectrum 65 
by connecting horizontal ATR (HATR) units using ZnSe crystal. ADKA was solubilized in 
aqueous solution buffered with 0.1 M Tris at pH 10 at a final concentration of 0.2 M. An 
aqueous solution of magnesium chloride hexahydrate (MgCl2.6H2O) at 0.4 M was prepared and 
added to the compound in equal volume. 
 
Theory. To investigate the structure and UV-visible spectroscopic properties of DKA 
derivative, we respectively selected DFT and time-dependent DFT (TD-DFT), combined to the 
PBE0 global hybrid, that includes 25% of exact exchange.
169,170
  
        Z                                                                                                                                          4  
        D(calc) [g/cm**3]                                                                                                        1.586   
        Mu(CuKa) [ /mm ]                                                                                                       3.871   
        F(000)                                                                                                                            1064   
        Crystal Size [mm]                                                                                  0.01 x  0.07 x  0.13   
Data Collection 
  
        Temperature (K)                                                                                                              293   
        Radiation [Angstrom]                                     CuKa      1.54178  
        Theta Min-Max                                                                                                     3.2,  75.0   
        Dataset                                                                                             -6:  0 ;   0: 33 ; -19: 20   
        Tot., Uniq. Data, R(int)                                                                         5047,   4535,  0.023   
        Observed data [I > 2.0 sigma(I)]                                                                                   2743   
 
Refinement 
  
        Nref, Npar                                                                                                            4535,  291   
        R, wR2, S                                                                                             0.0659, 0.2036, 1.03   
        Max. and Av. Shift/Error                                                                                      0.04, 0.00   
        Min. and Max. Resd. Dens. [e/Ang^3]                                                                -0.74, 0.75 
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We have followed a well-described and robust three-step strategy
171
: (1) the optimization of the 
ground-state structure; (2) the analytic determination of the vibrational spectrum to confirm the 
absence of imaginary frequencies; (3) the evaluation of the low-lying electronic excited-states. 
For all calculations, the self-consistent field convergence criteria have been tightened to, at 
least, 10
-8
 a.u. All the computations have been performed with the GAUSSIAN 03 suite of 
programs
172
, using default parameters and thresholds. The ground-state structures have been 
optimised with the 6-311G(d,p) basis set. The vibrational frequencies have been evaluated by 
the analytical determination of the Hessian matrix using the same level of theory whereas, for 
each molecule the first 15 vertical singlet excited-states have been computed by TD-PBE0. 
These UV/Vis spectra simulations have been performed with the doubly-polarised 6-
311+G(2d,p) basis set. The partial atomic charges have been computed with the Merz-Kollman 
approximation (so-called ESP charges) with the same methodology as the one used for TD-
DFT. In the following, the relative energies reported are Gibbs free energies (G) computed with 
the PCM-PBE0/6-311G(d,p) method, corrected by the total (internal) energies computed at the 
PCM-PBE0/6-311+G(2d,p) level of approximation. The bulk solvent effects are evaluated at 
each stage by means of the Conducting Polarisable Continuum Model (C-PCM)
173
, which 
divides the model into a solute part (QDKA) lying inside a cavity surrounded by the solvent 
continuum. As we target biological applications, water has been selected as medium. To build 
the cavity, we have used the UAKS radii especially optimised for the PBE0 functional. The 
TD-DFT calculations have been performed using the non-equilibrium procedure designed for 
the study of absorption processes
174
. 
 
3.3. Molecular modeling 
 
Model building. The HIV-1 IN/DNA model in its INSTI-inhibited form was initiated by 
overlaying the structures of HIV-1 IN CCD (1BL3C), Tn5 transposome (1MUS) and 
elvitegravir-bound PFV structure (3L2U) with their Cα positions of active-site residues Asp64, 
Asp116, and Glu152 (DDE motif). Bases of the 19-mer PFV DNA properly oriented into the 
HIV-1 IN CCD were mutated in order to correspond to the HIV-1 DNA sequence. Two Mg
2+
 
ions were then modeled into the HIV-1 active site based on the two Mn
2+
 ions coordinates from 
PFV structure and glutamate 152 residue (E152) was reoriented to interact with Mg
2+
 ions. 
Coordinated water molecules present in both HIV-1 IN CCD and Tn5 transposome crystal 
structure were then merged into the HIV-1 model to complete the octahedral geometry of the 
two Mg
2+
 ions.  
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The slightly resolved active site loop (residues 141-148) was removed and replaced by the 
equivalent PFV IN loop (residues 210-217), after which residues were mutated to correspond to 
the HIV-1 IN sequence. To remove bad intramolecular contacts without altering the 
architecture of the binding site, the resulting model was energy-minimized by 500 steps of 
steepest descent using CHARMm force field and Generalized Born (GB) model as solvation 
treatment implemented in Discovery Studio 2.5.
160
 Coordinates of model are available upon 
request to the authors. 
 
Docking. Docking of quinolone compounds into the HIV-1 IN/DNA model was carried 
out using GOLD (version 1.3.1) Software.
164
 All compounds were modelled by considering the 
stable conformation previously identified by experimental and theoretical studies. The binding 
region was defined as a 15 Å radius sphere centered on Mg
2+
 ions chelated by E152. An 
octahedral geometry was imposed on the two Mg
2+
 ions whereas explicit water molecules were 
allowed to switch on and off and to rotate around their three principal axes. For the 30 genetic 
algorithm (GA) runs performed, a total of 100 000 genetic operations were carried out on five 
islands, each containing 100 individuals. The niche size was set to 2, and the value for the 
selection pressure was set to 1.1. Genetic operator weights for crossover, mutation, and 
migration were set to 95, 95 and 10, respectively. The scoring function used to rank the 
docking was Goldscore. Among the 30 poses generated for each compound, the best-docked 
was principally based on ligand binding position. The parameter used for identifying the best 
ligand binding position was the two-metal chelating mode of DKA chain with Mg
2+
 ions. 
IN/DNA/ligand complex obtained by docking studies were minimized using steepest descent 
method (10 kcal. mol
-1
. Å
-1 
convergence) followed by conjugate gradient minimization (0.0001 
kcal. mol
-1
. Å
-1 
convergence) imposing the coplanarity of the diketoacid moiety. All complexes 
were minimized using CHARMm force field and GB model as solvation treatment 
implemented in Discovery Studio 2.5.
160
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